var title_f37_31_38384="Hypothal pituitary testic axis";
var content_f37_31_38384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypothalamic-pituitary-testicular axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the hypothalamic-pituitary-testicular axis shows the site of action of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the testes. Testosterone (T) and inhibin are produced by the testes. Testosterone has a negative feedback on the hypothalamus and LH production, while inhibin has a negative feedback on FSH production.",
"    <div class=\"footnotes\">",
"     C: cholesterol; GnRH: gonadotropin releasing hormone.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Griffin JE, Wilson JD, in: Metabolic Control and Disease, 8th ed, Bondy PK, Rosenberg LE (Eds) Saunders, Philadelphia, 1980, p. 1535.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38384=[""].join("\n");
var outline_f37_31_38384=null;
var title_f37_31_38385="Pheochromocytoma MRI";
var content_f37_31_38385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Pheochromocytoma in the adrenal gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance imaging (MRI) findings in adrenal pheochromocytomas. Left panel: Sagittal MRI demonstrates a mass (white arrow) displacing the inferior vena cava anteriorly (black arrow). This caval displacement is typically seen with tumors arising in the adrenal gland. Right panel: Coronal MRI of the abdomen demonstrates a large mass in the right adrenal bed (arrow), lying immediately superior to the kidney. The low signal intensity in the center is caused by hemorrhage into the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38385=[""].join("\n");
var outline_f37_31_38385=null;
var title_f37_31_38386="Lentigines before laser therapy";
var content_f37_31_38386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Lentigines on the dorsal hands before laser treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38386=[""].join("\n");
var outline_f37_31_38386=null;
var title_f37_31_38387="Manganese: Drug information";
var content_f37_31_38387=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Manganese: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/10/25763?source=see_link\">",
"    see \"Manganese: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F807895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mangimin [OTC];",
"     </li>",
"     <li>",
"      Mn-50&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dietary Supplement;",
"     </li>",
"     <li>",
"      Trace Element, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 2.3 mg/day; Females: 1.8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation: 2.6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Deficiency prevention:",
"     </b>",
"     I.V.: 150-800",
"     <b>",
"      mcg",
"     </b>",
"     /day usually administered in TPN solutions",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F191243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-6 months: 0.003 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 0.6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 1.2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: Males: 1.9 mg/day; Females: 1.6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: Males: 2.2 mg/day; Females: 1.6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Deficiency prevention:",
"     </b>",
"     I.V.: 2-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/day usually administered in TPN solutions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use caution in premature neonates; manganese chloride solution for injection contains aluminum.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F191238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; manganese chloride solution for injection contains aluminum.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F191239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; dose may need to be decreased or withheld.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as chelated:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mn-50&trade;: Elemental manganese 16.7 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride [preservative free]: Elemental manganese 0.1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: Elemental manganese 0.1 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as aspartate: 93 mg [elemental manganese 25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as chelated: Elemental manganese 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mangimin: Elemental manganese 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as gluconate: Elemental manganese 5.7 mg, 600 mg [elemental manganese 50 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F191226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, tablet: May be administered with a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection: Do not administer I.M. or by direct I.V. injection; acidic pH of the solution may cause tissue irritations and it is hypotonic; administer after dilution in volume of fluid &ge;100 mL",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trace element added to total parenteral nutrition (TPN) solution to prevent manganese deficiency; orally as a dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Manganese sulfate may be confused with magnesium sulfate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct I.M. or I.V. injection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract impairment; dose may need to be decreased or withheld.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose may need to be decreased or withheld.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Manganese chloride solution for injection contains aluminum; use caution with impaired renal function and in premature infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Due to its highly acidic pH (pH 2.0), direct I.V. or I.M. injection is contraindicated; may result in severe tissue damage.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Manganese crosses the placenta and can be detected in placental tissue and cord blood (Osada, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F191241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F191230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manganese is found in breast milk. Normal concentrations of manganese in human milk are generally lower than cow's milk or those found in food sources, but absorption from human milk is higher (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Manganese Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (10 mL): $2.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Manganese Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (10 mL): $4.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Manganese Aspartate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     93 mg (100): $11.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Manganese Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (90): $8.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mangimin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $6.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F191221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic manganese plasma level",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F191224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Whole blood: 6-12 mcg/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cofactor in many enzyme systems, stimulates synthesis of cholesterol and fatty acids in liver, and influences mucopolysaccharide synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentrated in mitochondria of pituitary gland, pancreas, liver, kidney, and bone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Bile (primarily); urine (negligible)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: The National Academies Press, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, ;81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/31/38387/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9586 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38387=[""].join("\n");
var outline_f37_31_38387=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F807895\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191244\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191236\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191243\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191237\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191238\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191239\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191223\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191212\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191226\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191249\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191229\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191216\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299643\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221444\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207726\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191241\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191230\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323359\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191221\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191224\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191215\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191228\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9586|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/10/25763?source=related_link\">",
"      Manganese: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38388="Thyroid gland dysfunction in HIV-infected patients";
var content_f37_31_38388=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroid gland dysfunction in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     Melissa Weinberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     Morris Schambelan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38388/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/31/38388/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early AIDS epidemic, the diverse endocrine manifestations of HIV infection were more often a consequence of opportunistic infections (OIs), neoplasms, or concomitant systemic illness. The widespread use of potent antiretroviral therapy (ART) has led to a decline in the incidence of glandular infiltration by OIs and neoplasms and has generated increased attention toward the metabolic complications of HIV therapy, including insulin resistance, dyslipidemia, and alterations in body fat distribution.",
"   </p>",
"   <p>",
"    This topic review will address the assessment and management of thyroid disorders in patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    Issues related to pituitary and adrenal disorders, insulin resistance, bone and calcium disorders, and changes in sex hormones are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=see_link\">",
"     \"Pituitary and adrenal gland dysfunction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the diagnosis and treatment of thyroid disorders in a patient with HIV infection does not differ from that in an immunocompetent individual. There are, however, some special considerations. HIV infection may cause changes in thyroid function that are adaptive and do not require treatment. Furthermore, many of the signs and symptoms of thyroid dysfunction are nonspecific and can overlap with other non-endocrine disorders that are common in HIV-infected patients. Finally, some medications that are used to treat HIV infection and its complications can induce thyroid dysfunction (",
"    <a class=\"graphic graphic_table graphicRef82984 \" href=\"mobipreview.htm?14/51/15163\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLANDULAR INFECTION AND INFILTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection by a diverse array of organisms, as well as HIV-associated malignancies (ie, Kaposi's sarcoma and lymphoma), have been detected in the thyroid gland (",
"    <a class=\"graphic graphic_table graphicRef72716 \" href=\"mobipreview.htm?17/62/18413\">",
"     table 2",
"    </a>",
"    ). Such occurrences were far more common prior to the widespread introduction of potent ART, although they may still be observed in patients not receiving ART or who have antiretroviral drug resistant infection.",
"   </p>",
"   <p>",
"    Tissue is generally required for a definitive diagnosis. Fine needle aspiration (FNA) biopsy of the thyroid is safe, effective, and widely available. Standard functional testing should also be performed since clinically significant thyroid dysfunction may accompany glandular infection or infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ALTERATIONS IN THYROID FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disturbances in thyroid function can lead to hypo- or hyperthyroidism, which can be clinically overt or minimally symptomatic. The clinical presentation and diagnosis of thyroid dysfunction is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .) The effect of HIV infection on thyroid function is discussed below.",
"   </p>",
"   <p>",
"    The clinical status of the HIV-infected patient is closely linked to the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of thyroid dysfunction. Asymptomatic HIV-positive patients with stable body weight usually maintain clinically normal thyroid function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a study of 202 stable HIV-infected patients, there were no thyroid abnormalities found in the 20 treatment-na&iuml;ve patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, changes similar to those seen in non-thyroidal illness (NTI) in HIV-seronegative individuals are often present in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/4\">",
"     4",
"    </a>",
"    ]. NTI is generally characterized by low-normal thyroid-stimulating hormone (TSH), low tri-iodythyronine (T3), high reverse T3 (rT3), and normal free thyroxine (T4) levels due to impaired peripheral T4 to T3 conversion and reduced rT3 clearance. Low T3 levels in NTI may be adaptive, by lowering metabolic rate and decreasing protein catabolism, in the setting of systemic illness or reduced caloric intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, T3 levels are often higher and reverse T3 levels lower in AIDS patients than expected for NTI, raising concern that these protective effects may be compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/6\">",
"     6",
"    </a>",
"    ]. These differences in T3 levels are not explained by the increased levels of thyroid hormone-binding globulin (TBG) seen in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/7\">",
"     7",
"    </a>",
"    ]. Reductions in T3 levels, however, are often observed in AIDS patients with acute secondary infection and anorexia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One cross-sectional multicenter study of 350 HIV-infected patients suggested that the prevalence of hypothyroidism was high (ie, 16 percent), although there was no HIV-seronegative control group for comparison [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk of hypothyroidism was increased among patients with lower CD4 counts. Symptoms ranged from overt hypothyroidism (2.6 percent) to subclinical disease (6.6 percent) to an isolated low free T4 level (6.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effects of medications on thyroid function",
"    </span>",
"    &nbsp;&mdash;&nbsp;By increasing clearance of thyroid hormone, medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    can precipitate hypothyroidism in patients with marginal thyroid reserve. Patients receiving replacement therapy with thyroxine may also require higher doses if taking these medications.",
"   </p>",
"   <p>",
"    HIV patients coinfected with hepatitis C who are treated with interferon-alpha (INF-alpha) may develop autoimmune thyroid diseases (AITD) such as Graves' disease and Hashimoto's thyroiditis, as well as subacute or destructive thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/9\">",
"     9",
"    </a>",
"    ]. The management of treatment-induced side effects for chronic hepatitis C is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When effective ART leads to immune reconstitution, AITD can result from the production of new immune cells targeting thyroid antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/10\">",
"     10",
"    </a>",
"    ]. Such patients typically present with signs and symptoms of Graves' disease one to two years after beginning ART. Immune reconstitution can also lead to development of Hashimoto's thyroiditis, which may explain reports suggesting an increased prevalence of subclinical hypothyroidism among patients taking ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment and treatment of thyroid function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic changes in thyroid function tests described above usually do not require treatment and must be interpreted in their appropriate clinical context. If an HIV-infected patient presents with typical signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of hypo- or hyperthyroidism (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    ), TSH should be the initial laboratory test ordered. If the TSH is normal, but there is still reason to suspect secondary (pituitary) hypothyroidism, then a free T4 must also be checked. Even though some studies have reported increased prevalence of hypothyroidism in HIV-infected populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38388/abstract/8\">",
"     8",
"    </a>",
"    ], we would not recommend routine screening until further data demonstrate clear clinical benefit.",
"   </p>",
"   <p>",
"    Those patients with clinically significant and biochemically confirmed hypothyroidism should initially be prescribed low doses of replacement therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    25 to 50 mcg daily). Gradual dose titration and monitoring of thyroid function tests may avoid exacerbation of AIDS-related cachexia in affected patients.",
"   </p>",
"   <p>",
"    The management of HIV-infected patients with hyperthyroidism is similar to that for non-HIV-infected individuals, with the notable exception that a tender thyroid gland in a patient with advanced HIV disease requires an FNA to exclude an OI (eg, pneumocystis). Thyroid nodules also require FNA to rule out malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early AIDS epidemic, endocrine abnormalities were usually due to infiltrative diseases and systemic illness. In the era of potent ART, there has been a decline in opportunistic infections and malignancies, but an increased incidence of metabolic complications, some related to medications. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the diagnosis of thyroid disorders in a patient with HIV infection does not differ from that in an immunocompetent individual. HIV infection, however, may cause changes in thyroid function that are adaptive and do not require treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Infections by a diverse array of organisms, as well as HIV-associated malignancies, have been reported in the thyroid gland. Tissue is generally required for a definitive diagnosis, particularly in the patient with advanced immunosuppression. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glandular infection and infiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical status of the HIV-infected patient is closely linked to the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of thyroid dysfunction. Patients with AIDS may have laboratory evidence of non-thyroidal illness and, in patients on ART, there may be an increased prevalence of hypothyroidism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Alterations in thyroid function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain medications, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      , can precipitate hypothyroidism in patients with marginal thyroid reserve.",
"     </li>",
"     <li>",
"      Immune reconstitution after initiation of potent ART can also lead to Graves' disease and Hashimoto's thyroiditis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effects of medications on thyroid function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of hypo- and hyperthyroidism in the HIV-infected patient is similar to the approach in the HIV-seronegative patient. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessment and treatment of thyroid function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in seronegative patients, a fine needle aspiration (FNA) biopsy of thyroid nodules should be performed to exclude malignancy. In addition, FNA should be done in an AIDS patient with a tender gland to exclude an opportunistic infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessment and treatment of thyroid function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/1\">",
"      Hommes MJ, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990; 39:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/2\">",
"      Lambert M. Thyroid dysfunction in HIV infection. Baillieres Clin Endocrinol Metab 1994; 8:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/3\">",
"      Madeddu G, Spanu A, Chessa F, et al. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clin Endocrinol (Oxf) 2006; 64:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/4\">",
"      Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996; 17:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/5\">",
"      Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the \"euthyroid sick syndrome\". Endocr Rev 1982; 3:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/6\">",
"      LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/7\">",
"      Grunfeld C, Pang M, Doerrler W, et al. Indices of thyroid function and weight loss in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1993; 42:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/8\">",
"      Beltran S, Lescure FX, Desailloud R, et al. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin Infect Dis 2003; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/9\">",
"      Carella C, Mazziotti G, Amato G, et al. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004; 89:3656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38388/abstract/10\">",
"      Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000; 85:4254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3744 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-113.53.254.124-160CFEADCC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38388=[""].join("\n");
var outline_f37_31_38388=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLANDULAR INFECTION AND INFILTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALTERATIONS IN THYROID FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effects of medications on thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment and treatment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3744|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/51/15163\" title=\"table 1\">",
"      HIV medications affecting thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/62/18413\" title=\"table 2\">",
"      OIs HIV endocrine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38389="Pancreas histology in SDS";
var content_f37_31_38389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreas histology in Shwachman-Diamond Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pancreatic duct is shown (center). A) Pancreatic biopsy in a 6-year-old boy with Shwachman-Diamond Syndrome shows  extensive replacement of the exocrine pancreas by adipose tissue  with remaining small islands of parenchyma. B) Extensive fat surrounding  acini (large arrows) with poorly granulated exocrine cells  and naked islets (small arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Shimamura, A. Shwachman-Diamond Syndrome. Seminars in Hematology 2006; 43:178. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38389=[""].join("\n");
var outline_f37_31_38389=null;
var title_f37_31_38390="Extensor tendon injury of the distal interphalangeal joint (mallet finger)";
var content_f37_31_38390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38390/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38390/contributors\">",
"     Rebecca Bassett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38390/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38390/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38390/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38390/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/31/38390/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mallet finger injury is the most common closed tendon injury of the finger. The injury occurs most often in the workplace or during contact or ball-handling sports. It is most common in young to middle-aged males, which may reflect their higher rates of participation in such sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of mallet finger injuries will be reviewed here. Other finger injuries are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28581?source=see_link\">",
"     \"Flexor tendon injury of the distal interphalangeal joint (jersey finger)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic disruption of the terminal slip of the extensor tendon at the distal interphalangeal (DIP) joint is commonly referred to as a mallet finger (or less often as a baseball or drop finger) (",
"    <a class=\"graphic graphic_figure graphicRef50968 \" href=\"mobipreview.htm?18/23/18801\">",
"     figure 1",
"    </a>",
"    ). The terminal slip is responsible for extension of the DIP joint. A zone of relative avascularity just proximal to the extensor tendon insertion predisposes the tendon to injury at this site. A more detailed discussion of finger anatomy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mallet finger occurs most commonly during collision sports, such as American football and rugby, or ball-handling sports, such as basketball and baseball. The injury is usually caused by a direct blow to the tip of the finger, such as when a ball strikes the fingertip or the fingertip strikes a rigid surface (",
"    <a class=\"graphic graphic_figure graphicRef66023 \" href=\"mobipreview.htm?14/24/14721\">",
"     figure 2",
"    </a>",
"    ). The axial load from the blow causes sudden, forceful flexion of the distal phalanx. This flexion damages the extensor tendon where it attaches to the proximal portion of the distal phalanx. Less frequently, a mallet finger may occur as part of finger injuries involving dorsal lacerations or crushing mechanisms.",
"   </p>",
"   <p>",
"    With mallet finger injuries, the tendon may be partially torn, completely ruptured, or associated with an avulsion fracture of the distal phalanx. Unopposed flexion leads to a fixed flexion deformity (called extensor lag) at the DIP joint if the injury remains untreated (",
"    <a class=\"graphic graphic_picture graphicRef77830 \" href=\"mobipreview.htm?2/51/2879\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mallet finger most often involves the middle finger and next, most often the ring finger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with a mallet finger complain of pain over the dorsum of the distal interphalangeal (DIP) joint. Swelling, ecchymosis, and deformity may be present, especially if there is an avulsion fracture. The most characteristic feature is an inability to extend the DIP joint fully, resulting in a flexed DIP at rest (",
"    <a class=\"graphic graphic_picture graphicRef77830 \" href=\"mobipreview.htm?2/51/2879\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When evaluating DIP motion, it is important to isolate the function of the extensor tendon by holding the proximal interphalangeal (PIP) joint in full extension (",
"    <a class=\"graphic graphic_picture graphicRef65342 \" href=\"mobipreview.htm?23/10/23727\">",
"     picture 2",
"    </a>",
"    ). This minimizes the contribution of the central slip to DIP extension. With the PIP joint stabilized, test active extension at the DIP joint. The patient with a mallet finger will be unable to extend the distal phalanx actively but the joint usually can be extended passively.",
"   </p>",
"   <p>",
"    The degree of DIP angulation often reflects the severity of the tendon disruption. With full tears, there is greater than 30 degrees of extensor lag, and the DIP joint cannot be extended. Partial tears exhibit 5 to 20 degrees of extensor lag along with weak active extension. The development of extensor lag may be delayed by a few hours to a few days after the injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/1\">",
"     1",
"    </a>",
"    ]. Inability to fully extend the DIP joint passively suggests bony or soft tissue entrapment, and the need for surgical referral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As part of the complete examination of an injured digit, the clinician should assess the finger's neurovascular function and inspect the soft tissue for lacerations. The lateral stability of the DIP joint should be evaluated by placing a radial and then, ulnar stress on the joint. Comparison with the corresponding finger of the opposite hand can help to determine if laxity is present, which suggests a collateral ligament injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiography should be performed on all mallet finger deformities to evaluate for fractures of the distal phalanx and for alignment abnormalities. X-rays should include anterior-posterior (AP), lateral, and oblique views [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avulsion fractures and volar (palmar) subluxation of the distal phalanx are best seen on a true lateral view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50157 \" href=\"mobipreview.htm?8/30/8686\">",
"     image 1",
"    </a>",
"    ). Mallet finger injuries involving fractures of the base of the distal phalanx can be characterized according to the presence or absence of subluxation and the degree of involvement of the articular surface in the DIP fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of mallet finger injuries can be managed by primary care clinicians, but more complex injuries warrant evaluation by an orthopedic or hand surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Commonly accepted indications for surgical referral include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to achieve full passive extension of the DIP joint",
"     </li>",
"     <li>",
"      Full laceration of the extensor tendon",
"     </li>",
"     <li>",
"      Volar (palmar) subluxation of the distal phalanx",
"     </li>",
"     <li>",
"      Fracture involving greater than 30 percent of the joint surface",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An inability to passively extend the joint suggests the presence of entrapped bony or soft tissue, while volar subluxation is associated with worse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLEX MALLET FINGER: SPLINTING OR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mallet fingers that involve large displaced fractures (greater than one-third of the articular surface) or joint displacement have traditionally been thought to lead to a permanent deformity and were treated surgically. However, the results of two systematic reviews and several case series suggest that nonsurgical treatment may be appropriate in many such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one retrospective study, treatment of 22 closed mallet finger fractures involving one to two thirds of the articular surface with six weeks of extension splinting achieved similar results to surgical correction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/10\">",
"     10",
"    </a>",
"    ]. The assessed outcomes included residual extensor lag, pain, function, and satisfaction with finger appearance. Injuries with palmar subluxation were more prone to joint disfigurement. All patients reported minimal functional impairment and pain, and there was no significant difference in outcomes between patients managed with splinting alone or with surgical repair. The authors concluded that nonoperative management is appropriate for most cases, but that surgical pinning may be necessary for cases that are refractory to splinting (eg, demonstrate persistent extensor lag) or involve swan-neck deformities.",
"   </p>",
"   <p>",
"    The patient's preferences and goals should be taken into account when deciding whether to perform surgery. Factors to consider include the patient's ability to comply rigorously with conservative therapy, the amount of functional disability present including the degree of extension loss, and the time since the initial injury. Surgical treatment carries the risk of infection and a stiff DIP joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute mallet finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of mallet finger treatment is to maximize the function of the distal interphalangeal (DIP) joint while minimizing discomfort. The majority of mallet fingers are amenable to treatment with immobilization (ie, splinting), but some complex injuries warrant surgical referral. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A systematic review identified only four randomized or quasi-randomized placebo-controlled trials, involving a total of 278 patients that compared treatments for mallet finger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/5\">",
"     5",
"    </a>",
"    ]. One trial included in the review found no difference in outcomes or complications between fractures treated with splinting versus surgery using wire fixation.",
"   </p>",
"   <p>",
"    The general consensus among experts is that uncomplicated mallet finger injuries without DIP joint subluxation are best treated with splinting. The central slip of the proximal interphalangeal (PIP) joint prevents excessive retraction of the damaged tendon, allowing close approximation and healing of the torn tendon sections to occur with splinting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts immobilize the DIP joint in full extension or slight hyperextension (5 to 15 degrees), while allowing full range of motion of the PIP joint. Clinical experience and the results of one cadaveric study that assessed the biomechanics of mallet finger injuries support this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Primary care and emergency clinicians should",
"    <strong>",
"     not",
"    </strong>",
"    attempt to reduce any displaced fractures before splinting because any reduction is unlikely to be maintained without surgery; mallet fingers with associated fractures are referred.",
"   </p>",
"   <p>",
"    The systematic review referred to above found insufficient evidence to determine the best method for splinting a mallet finger, and the results of two subsequent randomized trials are consistent with this conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/5\">",
"     5",
"    </a>",
"    ]. In a randomized trial involving 116 mallet fingers, patients with custom-made splints had fewer treatment failures compared to those with stack splints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/14\">",
"     14",
"    </a>",
"    ]. Improved outcomes in patients treated with custom splints were noted in one other randomized trial of 64 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, several trials have found that splint type does not affect outcome. A randomized trial involving 60 patients reported that aluminum splints fit better and caused fewer skin-related complications than stack splints, but both splints were equally effective for enabling tendon healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/16\">",
"     16",
"    </a>",
"    ]. Another randomized trial of 77 patients reported no significant difference in extensor lag or complications based upon the type of splint selected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/17\">",
"     17",
"    </a>",
"    ]. We suggest selecting a splint based upon patient comfort in order to maximize compliance, provided the splint is sturdy and ensures adequate immobilization and proper positioning.",
"   </p>",
"   <p>",
"    An aluminum splint can be applied to either the palmar or dorsal surface of the middle and distal phalanx (",
"    <a class=\"graphic graphic_picture graphicRef53614 \" href=\"mobipreview.htm?10/60/11215\">",
"     picture 3",
"    </a>",
"    ). If possible, the splint should be bent slightly to stabilize the DIP joint in 5 to 10 degrees of hyperextension. Hyperextension may be limited initially by swelling or skin tightness. A stack splint may be used provided the splint is sufficiently tight to prevent any DIP flexion (",
"    <a class=\"graphic graphic_picture graphicRef67892 \" href=\"mobipreview.htm?22/38/23136\">",
"     picture 4",
"    </a>",
"    ). Custom-made perforated splints similar to stack splints can be made for fingers that are difficult to fit and they provide better aeration. An Abouna splint or metal ring splints are generally not used because of patient discomfort.",
"   </p>",
"   <p>",
"    Care should be taken to avoid direct, sustained pressure from the splint on the area of the DIP joint. Excessive pressure or hyperextension can cause skin necrosis. The Kleinert modified dorsal splint attempts to avoid this complication by removing the middle third of the foam padding from the splint, thereby eliminating all direct pressure at the injury site (",
"    <a class=\"graphic graphic_picture graphicRef83565 \" href=\"mobipreview.htm?27/58/28591\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83566 \" href=\"mobipreview.htm?31/62/32737\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some instances, a swan neck deformity (indicating involvement of the central slip) accompanies a mallet finger injury. In such cases, both the DIP and the PIP joints should be immobilized in full extension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/13\">",
"     13",
"    </a>",
"    ]. Most cases heal well with splinting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/9\">",
"     9",
"    </a>",
"    ]. A swan neck deformity appears as a hyperextended PIP joint and a flexed DIP joint (",
"    <a class=\"graphic graphic_figure graphicRef55390 \" href=\"mobipreview.htm?13/4/13379\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIP joint extension splinting is performed for six to eight weeks. The DIP joint",
"    <strong>",
"     MUST",
"    </strong>",
"    be maintained in full extension throughout the entire period, including during sleep. Adherence to this instruction is essential. The most common reason for treatment failure is noncompliance. Whenever the splint is removed (eg, to clean the finger or change the splint), the patient must support the distal fingertip in full extension at all times. Should DIP joint extension be lost at any point during the initial treatment period, the treatment clock is reset and an additional six weeks of splinting must be performed. The patient should be seen every one to two weeks to check on compliance and complications.",
"   </p>",
"   <p>",
"    After six to eight weeks of continuous extension splinting with the DIP joint maintained in full extension, the joint is reexamined and active extension assessed. If the patient is able to achieve full extension, an additional two to four weeks of nighttime splinting is performed.",
"   </p>",
"   <p>",
"    Splinting should be maintained for ALL athletic events for another six weeks. If necessary, the foam padding of the aluminum splint may be removed and the aluminum secured directly to the dorsum of the finger to allow the returning athlete to fit the finger into a glove [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11\">",
"     11",
"    </a>",
"    ]. Active range-of-motion exercises are encouraged in these patients to minimize DIP stiffness.",
"   </p>",
"   <p>",
"    If a significant extension lag (ie, volar angulation) persists following the initial six weeks of splinting, the splint is reapplied for up to six additional weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11\">",
"     11",
"    </a>",
"    ]. As with the initial treatment period, the DIP joint MUST be strictly maintained in full extension throughout the second treatment period. The joint should be reexamined every two weeks during this second treatment period. Once an acceptable outcome is achieved, a night splint is used for two to four additional weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic mallet finger",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic mallet fingers are those that go untreated for four weeks or longer. Several small case series suggest that splinting chronic mallet fingers that present within 12 weeks of the initial injury can improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ]. All patients in these studies were treated with a stack or aluminum splint for 6 to 10 weeks. Extensor lag following treatment averaged 10 degrees.",
"   </p>",
"   <p>",
"    Treatment of chronic mallet finger consists of DIP extension splinting lasting from 8 to 20 weeks. Patients should be warned about the increased risk of deformity and other complications with delayed presentation and treatment. A successful outcome may be more likely if the injury site appears to be actively inflamed, as suggested by continued swelling, erythema, or tenderness over the DIP joint, and there are no signs of complications, such as scarring or retraction of the tendon. If conservative treatment is unsuccessful, the patient should be referred to a hand surgeon.",
"   </p>",
"   <p>",
"    Mallet fingers that fail to improve with splinting may be suitable for surgical repair if there is significant residual extensor lag (&gt;30 degrees) or functional limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/4\">",
"     4",
"    </a>",
"    ]. Such patients should be referred to a hand surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RETURN TO WORK OR SPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mallet finger injuries may return to sport, provided proper hyperextension is maintained with adequate bracing. However, most contact sports are best avoided in the first six to eight weeks following injury. After the initial six to eight weeks of splinting, an additional six to eight weeks of buddy taping or splinting should be used during athletics. Clinicians must reinforce the importance of strict patient compliance with splinting and the possible long-term complications that will result from noncompliance or returning to play prematurely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of mallet finger may result from lack of timely recognition and treatment, which may lead to chronic stiffness and deformity of the DIP joint (",
"    <a class=\"graphic graphic_picture graphicRef77830 \" href=\"mobipreview.htm?2/51/2879\">",
"     picture 1",
"    </a>",
"    ). Complications may also occur as a result of splinting or surgery. Nearly all patients will have a small degree of extensor lag that does not interfere with daily activities.",
"   </p>",
"   <p>",
"    Most complications from splinting are minor and resolve once treatment is concluded. Such complications include allergic reactions to tape, skin maceration and ulceration, and joint pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11\">",
"     11",
"    </a>",
"    ]. Skin complications can be minimized by avoiding hyperextension that causes pain or skin blanching [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/13\">",
"     13",
"    </a>",
"    ]. Joint pain can be minimized by alternating between dorsal and volar splinting during the six week treatment period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11\">",
"     11",
"    </a>",
"    ]. A small noticeable lump over the DIP joint may persist for six to eight months following splinting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A five year follow-up study of 31 patients treated with splinting for mallet finger found that extensor lag averaged 8 degrees, osteoarthritic changes developed in 11 patients, and a swan neck deformity occurred in 9 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical complications are more complex and more likely to persist. They include infection, nail plate deformity, joint incongruity, osteonecrosis, loss of reduction, hardware failure, and DIP joint deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38390/abstract/21\">",
"     21",
"    </a>",
"    ]. Some complications require further corrective surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=see_link\">",
"       \"Patient information: Hand pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/17/2323?source=see_link\">",
"       \"Patient information: Common finger injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mallet finger injuries are the result of a partial or complete rupture of the extensor tendon's terminal insertion distal to the distal interphalangeal (DIP) joint. They are caused by a forced flexion injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination findings in a mallet finger injury include pain and swelling over the dorsum of the DIP joint, a DIP flexor deformity, and an inability to actively extend the DIP joint. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical referral should be obtained if the mallet finger is associated with a fracture, the DIP joint cannot be passively extended, or there is DIP joint subluxation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that uncomplicated mallet finger injuries be treated by maintaining the DIP joint in full extension or minimally hyperextended using an appropriate splint (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It is crucial that patients not allow flexion of the DIP at any time during the initial period of splinting (generally six to eight weeks). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DIP splinting is performed continuously for six to eight weeks. If no extensor lag exists at the end of this period, night splinting is then performed for two additional weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060044\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/1\">",
"      Bendre AA, Hartigan BJ, Kalainov DM. Mallet finger. J Am Acad Orthop Surg 2005; 13:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/2\">",
"      McCue FC 3rd, Meister K. Common sports hand injuries. An overview of aetiology, management and prevention. Sports Med 1993; 15:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/3\">",
"      Lee SJ, Montgomery K. Athletic hand injuries. Orthop Clin North Am 2002; 33:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/4\">",
"      Tuttle HG, Olvey SP, Stern PJ. Tendon avulsion injuries of the distal phalanx. Clin Orthop Relat Res 2006; 445:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/5\">",
"      Handoll HH, Vaghela MV. Interventions for treating mallet finger injuries. Cochrane Database Syst Rev 2004; :CD004574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/6\">",
"      Geyman JP, Fink K, Sullivan SD. Conservative versus surgical treatment of mallet finger: a pooled quantitative literature evaluation. J Am Board Fam Pract 1998; 11:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/7\">",
"      Weber P, Segm&uuml;ller H. [Non-surgical treatment of mallet finger fractures involving more than one third of the joint surface: 10 cases]. Handchir Mikrochir Plast Chir 2008; 40:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/8\">",
"      Wehb&eacute; MA, Schneider LH. Mallet fractures. J Bone Joint Surg Am 1984; 66:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/9\">",
"      Facca S, Nonnenmacher J, Liverneaux P. [Treatment of mallet finger with dorsal nail glued splint: retrospective analysis of 270 cases]. Rev Chir Orthop Reparatrice Appar Mot 2007; 93:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/10\">",
"      Kalainov DM, Hoepfner PE, Hartigan BJ, et al. Nonsurgical treatment of closed mallet finger fractures. J Hand Surg Am 2005; 30:580.",
"     </a>",
"    </li>",
"    <li>",
"     Kiefhaber TR. Closed tendon injuries in the hand. Operative Techniques in Sports Medicine. 1996; 4:227. file://www.optechsportsmed.com/article/S1060-1872(96)80023-2/abstract (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/12\">",
"      Katzman BM, Klein DM, Mesa J, et al. Immobilization of the mallet finger. Effects on the extensor tendon. J Hand Surg Br 1999; 24:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/13\">",
"      Hart RG, Kleinert HE, Lyons K. The Kleinert modified dorsal finger splint for mallet finger fracture. Am J Emerg Med 2005; 23:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/14\">",
"      Warren RA, Norris SH, Ferguson DG. Mallet finger: a trial of two splints. J Hand Surg Br 1988; 13:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/15\">",
"      O'Brien LJ, Bailey MJ. Single blind, prospective, randomized controlled trial comparing dorsal aluminum and custom thermoplastic splints to stack splint for acute mallet finger. Arch Phys Med Rehabil 2011; 92:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/16\">",
"      Maitra A, Dorani B. The conservative treatment of mallet finger with a simple splint: a case report. Arch Emerg Med 1993; 10:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/17\">",
"      Pike J, Mulpuri K, Metzger M, et al. Blinded, prospective, randomized clinical trial comparing volar, dorsal, and custom thermoplastic splinting in treatment of acute mallet finger. J Hand Surg Am 2010; 35:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/18\">",
"      Patel MR, Desai SS, Bassini-Lipson L. Conservative management of chronic mallet finger. J Hand Surg Am 1986; 11:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/19\">",
"      Garberman SF, Diao E, Peimer CA. Mallet finger: results of early versus delayed closed treatment. J Hand Surg Am 1994; 19:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/20\">",
"      Okafor B, Mbubaegbu C, Munshi I, Williams DJ. Mallet deformity of the finger. Five-year follow-up of conservative treatment. J Bone Joint Surg Br 1997; 79:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38390/abstract/21\">",
"      Stern PJ, Kastrup JJ. Complications and prognosis of treatment of mallet finger. J Hand Surg Am 1988; 13:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 198 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38390=[""].join("\n");
var outline_f37_31_38390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLEX MALLET FINGER: SPLINTING OR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute mallet finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic mallet finger",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RETURN TO WORK OR SPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060044\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/198|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/30/8686\" title=\"diagnostic image 1\">",
"      Mallet finger with fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/198|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/23/18801\" title=\"figure 1\">",
"      Finger tendons expanded view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/24/14721\" title=\"figure 2\">",
"      Mallet finger mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/4/13379\" title=\"figure 3\">",
"      Swan neck deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/198|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/51/2879\" title=\"picture 1\">",
"      Mallet finger photo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/10/23727\" title=\"picture 2\">",
"      DIP examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/60/11215\" title=\"picture 3\">",
"      DIP basic splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/38/23136\" title=\"picture 4\">",
"      DIP stack splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/58/28591\" title=\"picture 5\">",
"      Kleinert finger splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/62/32737\" title=\"picture 6\">",
"      Kleinert finger splint in place",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28581?source=related_link\">",
"      Flexor tendon injury of the distal interphalangeal joint (jersey finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/17/2323?source=related_link\">",
"      Patient information: Common finger injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38391="An overview of angioedema: Pathogenesis and causes";
var content_f37_31_38391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   An overview of angioedema: Pathogenesis and causes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38391/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38391/contributors\">",
"     Clifton O Bingham, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38391/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38391/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38391/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38391/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/31/38391/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema is self-limited, localized swelling of the skin or mucosal tissues, which results from extravasation of fluid into the interstitium due to a loss of vascular integrity. Angioedema may occur in isolation, accompanied by urticaria, or as a component of anaphylaxis.",
"   </p>",
"   <p>",
"    The pathogenesis and causes of angioedema will be reviewed here. The clinical features, diagnosis, differential diagnosis, and management of acute angioedema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the epidemiology of angioedema is limited. In a retrospective review of all hospital admissions in New York State over 13 years, angioedema was the second most common \"allergic\" disease to necessitate hospitalization, exceeded only by asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/1\">",
"     1",
"    </a>",
"    ]. The number of hospitalizations per year more than doubled during the study period, suggesting that the prevalence may be increasing. African Americans were disproportionately affected, as they accounted for 42 percent of the admissions for angioedema, but only 16 percent of the state's population.",
"   </p>",
"   <p>",
"    The epidemiology of specific forms of angioedema, such as hereditary angioedema due to C1 inhibitor deficiency, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema results from a loss of vascular integrity that allows fluid to move into tissues. Exposure of the vasculature to inflammatory mediators causes dilation and increased permeability of capillaries and venules.",
"   </p>",
"   <p>",
"    In contrast, edema associated with cardiovascular, renal, and liver disease (eg, heart failure, renal failure, venous obstruction) is usually due to an alteration in Starling's forces, such as an increase in intracapillary pressure or a reduction in the plasma oncotic pressure (ie, any cause of severe hypoalbuminemia) in the presence of normal vasculature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The known causes of angioedema can be subdivided into three groups, depending upon the underlying mechanism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mast cell-mediated etiologies, in which angioedema results from release of mast cell-derived mediators that increase vascular permeability. Mast cell mediated angioedema is associated with urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pruritus in most cases.",
"     </li>",
"     <li>",
"      Bradykinin-mediated etiologies, in which angioedema results from the generation of bradykinin and complement-derived mediators that increase vascular permeability. These forms of angioedema are",
"      <strong>",
"       not",
"      </strong>",
"      associated with urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pruritus and are diagnosed and treated differently from other types of angioedema. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"       \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Etiologies of unknown mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mast cell-mediated etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell-mediated angioedema is associated with urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritus in most cases. This form of angioedema is pathologically similar to urticaria, although it takes place in the deeper levels of the dermis and subcutaneous tissues. Mast cells can be activated via several mechanisms (",
"    <a class=\"graphic graphic_table graphicRef58834 \" href=\"mobipreview.htm?11/8/11403\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20936?source=see_link\">",
"     \"Mast cells: Surface receptors and signal transduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Activated mast cells release inflammatory mediators, including histamine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , leukotriene C4, and prostaglandin D2, which cause dilation of venules in the dermis and enhance venule permeability, with resultant tissue edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of mast cell-mediated angioedema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute angioedema, with or without other symptoms of allergic reactions, may be triggered by foods, drugs, latex, exercise, the stings of various insects, and a growing list of other uncommon allergens.",
"   </p>",
"   <p>",
"    Angioedema resulting from an allergic reaction is usually accompanied by other signs and symptoms, including urticaria, pruritus, flushing, throat tightness, bronchospasm, and hypotension. Angioedema can occur in isolation, although this is uncommon. As an example, in a series of 112 patients with penicillin allergy confirmed by skin testing, only one patient had experienced isolated angioedema without urticaria during the presenting allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic type of allergic reaction results from IgE-mediated, Gell and Coombs type I hypersensitivity (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"mobipreview.htm?13/11/13500\">",
"     table 2",
"    </a>",
"    ). The reaction typically occurs within minutes to two hours following exposure to the trigger. However, IgE-mediated allergic reactions are occasionally delayed in onset. Allergy to certain meats (lamb, beef,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pork) can lead to reactions with prominent angioedema, beginning two to six hours after ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Direct mast cell release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells can be nonspecifically stimulated to release their proinflammatory mediators by certain medications and pharmaceuticals, such as opiates and radiocontrast media. This type of angioedema is accompanied by urticaria in most cases. IgE is not involved, and skin testing or in vitro testing is not helpful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Aspirin and NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , can cause acute",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    and can exacerbate chronic",
"    <span class=\"nowrap\">",
"     urticaria/angioedema.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chronic urticaria with or without angioedema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This adverse effect of NSAIDs is believed to be due to the pharmacologic properties of the medications on mast cells. NSAIDs inhibit the enzyme cyclooxygenase 1 (COX 1), the enzyme which mediates the generation of prostaglandins from arachidonic acid within mast cells and other leukocytes. NSAID administration results in increased formation of proinflammatory mediators, leading to angioedema in some individuals.",
"   </p>",
"   <p>",
"    NSAIDs that nonselectively inhibit both COX 1 and 2 enzymes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , and most others) can potentially induce this effect. Selective COX 2 inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , are tolerated by most patients who have reacted to nonselective NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/4\">",
"     4",
"    </a>",
"    ], although rare exceptions are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/5\">",
"     5",
"    </a>",
"    ]. Management of patients with these reactions is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link&amp;anchor=H15#H15\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chronic urticaria with or without angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic urticaria refers to recurrent urticaria that is present most days of the week for a period of six weeks or longer. Angioedema is present in up to 40 percent of patients with chronic urticaria, and most affected patients have hives regularly and angioedema occasionally when the symptoms are most severe.",
"   </p>",
"   <p>",
"    Chronic urticaria may persist over months to years and is most common in women, particularly between the ages of 40 and 50 years. In most cases of chronic",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    a specific cause cannot be identified. This disorder is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bradykinin-mediated etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema can occur due to vasodilation and increased vascular permeability resulting from inflammatory mediators, especially bradykinin, generated by other cell types. Mast cells are not believed to be involved in this form of angioedema, and pruritus and urticaria are",
"    <strong>",
"     absent",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Perturbations in kinin pathways resulting directly from the actions of medications (eg, angiotensin converting enzyme inhibitors) or from defects in the complement system are the main causes of bradykinin-mediated angioedema. The treatment of bradykinin-induced angioedema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors account for 20 to 30 percent of all angioedema cases presenting to emergency departments in both community and tertiary-care settings. ACE inhibitor-induced angioedema most often affects the lips, tongue, mouth, larynx, pharynx, and subglottic tissues. Urticaria and itching are absent. ACE inhibitors can also cause intestinal edema, and the sudden onset of abdominal pain, nausea, and sometimes vomiting in an older adult should prompt inquiries about the use of ACE inhibitors. The epidemiology, pathophysiology, diagnosis, and management of patients with ACE inhibitor&ndash;induced angioedema is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37465?source=see_link\">",
"     \"ACE inhibitor-induced angioedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have linked the use of angiotensin II receptor blockers (ARBs), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    , with the development of angioedema, although the risk appears to be lower than with ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In the largest comparative study, the ONTARGET trial of over 17,000 patients treated with telmisartan or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    , the rate of angioedema was significantly lower with telmisartan (0.1 versus 0.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/6\">",
"     6",
"    </a>",
"    ]. The development of angioedema following therapy with ARBs is surprising since these drugs are not thought to affect kinin metabolism directly (",
"    <a class=\"graphic graphic_figure graphicRef67838 \" href=\"mobipreview.htm?20/45/21213\">",
"     figure 1",
"    </a>",
"    ). The administration of ARBs to a patient with past ACE inhibitor-induced angioedema is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link&amp;anchor=H30#H30\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'ACE inhibitor-induced angioedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitors and ARBs may also unmask deficiencies of C1 inhibitor (discussed in the next section) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hereditary and acquired angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema can occur in patients with abnormalities in the level or function of the regulatory complement protein C1 inhibitor (C1-INH, previously referred to as C1 esterase inhibitor) in association with increased levels of bradykinin. These disorders are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=see_link\">",
"     \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, both hereditary and acquired forms of C1-INH deficiency exist, with similar clinical manifestations. The main differences between the two conditions are the age of presentation and the underlying health of the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hereditary angioedema typically present in late childhood or early adolescence with angioedema following trauma, infection, dental procedures, or emotional stress, with an increasing frequency and severity of episodes with puberty, menses, and ovulation. These patients are otherwise healthy.",
"     </li>",
"     <li>",
"      In contrast, the acquired form typically occurs at an older age and most patients have an associated lymphoproliferative disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=see_link&amp;anchor=H4#H4\">",
"       \"Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\", section on 'Associated disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The symptoms with both forms of C1-INH deficiency can range in severity from a minor inconvenience to life-threatening laryngeal edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to estrogens, either through contraception, hormone replacement therapy, or pregnancy, may trigger attacks of angioedema in patients with hereditary angioedema disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link&amp;anchor=H19#H19\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Triggers and exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Etiologies of unknown mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several recognized causes of angioedema for which mechanisms are not defined. The treatment of these disorders is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Idiopathic angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic angioedema is the term applied to recurrent episodes of angioedema without urticaria, for which no explanation can be found after a thorough evaluation to exclude allergic disorders, drug reactions, and defects in complement pathways. The management of idiopathic angioedema is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both dihydropyridines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) and non-dihydropyridines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) have been implicated in causing angioedema, either of the skin or small bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. However, no mechanism has been proposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Fibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema without urticaria has been reported following fibrinolysis with streptokinase and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in patients treated acutely for stroke and thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H549662#H549662\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Angioedema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that have been reported to cause angioedema without urticaria include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and other biological agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/20-28\">",
"     20-28",
"    </a>",
"    ]. Inhaled cocaine has been implicated in uvular angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18165957\">",
"    <span class=\"h3\">",
"     Herbal medicines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several herbal medicines have been associated with angioedema, including garlic, sanyak, and Echballium elaterium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other rare causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare causes of angioedema include selected disorders with eosinophilia and urticarial vasculitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Disorders with eosinophilia",
"      </strong>",
"      &mdash; Angioedema is associated with a peripheral eosinophilia in two disorders, the hypereosinophilic syndrome and Gleich syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Approximately 15 percent of patients with the hypereosinophilic syndrome have angioedema and this diagnosis should be considered in patients with dramatic elevations in peripheral eosinophil counts (eg, &ge;1500",
"      <span class=\"nowrap\">",
"       eosinophils/microliter)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. The mechanisms of the angioedema in this disorder may involve the direct release of vasodilatory mediators from eosinophils or may reflect the activation of cutaneous mast cells by eosinophil-derived mediators. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The entity of episodic angioedema with eosinophilia (Gleich syndrome) is characterized by recurrent episodes of angioedema, urticaria, pruritus, fever, weight gain, elevated serum IgM, and leukocytosis with marked blood eosinophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/38-41\">",
"       38-41",
"      </a>",
"      ]. The level of blood eosinophilia parallels disease activity. The etiology of this syndrome is unknown but has been associated with upregulation of C5a receptors on eosinophils during episodes of disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/42\">",
"       42",
"      </a>",
"      ]. Gleich syndrome is now considered a type of hypereosinophilic syndrome (HES), although the absence of cardiac damage or other end-organ involvement and the episodic nature of the symptoms distinguish this condition from other forms of HES. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=see_link&amp;anchor=H4769463#H4769463\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Gleich's syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urticarial vasculitis",
"      </strong>",
"      &mdash; Angioedema may be observed in patients with hypocomplementemic urticarial vasculitis, in which IgG antiC1q is often identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38391/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. The urticarial lesions of urticarial vasculitis are variably painful, ecchymotic, and purpuric, and often leave residual bruising upon resolution. Systemic disease and fever may be present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/31/1523?source=see_link\">",
"       \"Patient information: Angioedema (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angioedema is self-limited, localized swelling of the skin or mucosal tissues. Angioedema may occur in isolation, accompanied by urticaria, or as a component of anaphylaxis.",
"     </li>",
"     <li>",
"      Angioedema results from a loss of vascular integrity, allowing fluid to move into the interstitial tissues, due to the presence of inflammatory mediators. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of angioedema can be divided into three groups based upon the underlying mechanism (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Causes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mast cell mediated-angioedema, such as allergic reactions, NSAIDs, agents that directly activate mast cells (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Mast cell-mediated etiologies'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Bradykinin-mediated angioedema, such as ACE inhibitors and hereditary and acquired forms of C1 inhibitor deficiency. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bradykinin-mediated etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes with unknown mechanisms, such as idiopathic angioedema and fibrinolytic agents. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Etiologies of unknown mechanism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/1\">",
"      Lin RY, Cannon AG, Teitel AD. Pattern of hospitalizations for angioedema in New York between 1990 and 2003. Ann Allergy Asthma Immunol 2005; 95:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/2\">",
"      Romano A, Viola M, Gu&eacute;ant-Rodriguez RM, et al. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006; 354:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/3\">",
"      Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009; 123:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/4\">",
"      Zembowicz A, Mastalerz L, Setkowicz M, et al. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003; 139:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/5\">",
"      Fontaine C, Bousquet PJ, Demoly P. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol 2005; 115:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/6\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/7\">",
"      van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/8\">",
"      Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002; 22:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/9\">",
"      Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/10\">",
"      Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/11\">",
"      Berkun Y, Shalit M. Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor. Ann Allergy Asthma Immunol 2001; 87:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/12\">",
"      Ricketti AJ, Cleri DJ, Ramos-Bonner LS, Vernaleo JR. Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment. Ann Allergy Asthma Immunol 2007; 98:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/13\">",
"      Turcu AF, White JA, Kulaga ME, et al. Calcium channel blocker-associated small bowel angioedema. J Clin Gastroenterol 2009; 43:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/14\">",
"      Southward J, Irvine E, Rabinovich M. Probable amlodipine-induced angioedema. Ann Pharmacother 2009; 43:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/15\">",
"      Hedner T, Samuelsson O, Lindholm L, et al. Precipitation of angioedema by antihypertensive drugs. J Hypertens Suppl 1991; 9:S360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/16\">",
"      Romano A, Pietrantonio F, Garcovich A, et al. Delayed hypersensitivity to diltiazem in two patients. Ann Allergy 1992; 69:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/17\">",
"      Sadick NS, Katz AS, Schreiber TL. Angioedema from calcium channel blockers. J Am Acad Dermatol 1989; 21:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/18\">",
"      Ottomeyer C, Hennerici MG, Szabo K. Raising awareness of orolingual angioedema as a complication of thrombolysis in acute stroke patients. Cerebrovasc Dis 2009; 27:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/19\">",
"      Walls RM, Pollack CV Jr. Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med 2000; 35:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/20\">",
"      Er F, Nia AM, Erdmann E. [67-year-old patient with speech disorder and dysphagia]. Dtsch Med Wochenschr 2008; 133:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/21\">",
"      Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/22\">",
"      Mackenzie M, Wood LA. Lingual angioedema associated with everolimus. Acta Oncol 2010; 49:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/23\">",
"      Mah&eacute; E, Morelon E, Lechaton S, et al. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007; 214:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/24\">",
"      Burches E, Garcia-Verdegay F, Ferrer M, Pelaez A. Amiodarone-induced angioedema. Allergy 2000; 55:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/25\">",
"      Krikorian RK, Quick A, Tal A. Angioedema following the intravenous administration of metoprolol. Chest 1994; 106:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/26\">",
"      Sendur OF, Turan Y, Berkit IK, Tastaban E. Angio-oedema in a patient treated with etanercept for rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009; 104:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/27\">",
"      Cooney C, Nagy A. Angio-oedema associated with risperidone. BMJ 1995; 311:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/28\">",
"      Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/29\">",
"      Kinsey CM, Howell M. A 27-year-old woman with a swollen uvula, chest pain, and elevated creatinine phosphokinase levels. Chest 2008; 133:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/30\">",
"      Hidalgo Mora JJ, Gim&eacute;nez de Llano E, Sempere Verd&uacute; E, Feli&uacute; Sagal&aacute; M. [Uvular angioedema after intranasal cocaine consumption]. Med Clin (Barc) 2002; 119:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/31\">",
"      Kestler A, Keyes L. Images in clinical medicine. Uvular angioedema (Quincke's disease). N Engl J Med 2003; 349:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/32\">",
"      Welling A. Enlarged uvula (Quincke's Oedema)--a side effect of inhaled cocaine?--A case study and review of the literature. Int Emerg Nurs 2008; 16:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/33\">",
"      Hur GY, Park HJ, Kim HA, et al. Identification of Dioscorea batatas (sanyak) allergen as an inhalant and oral allergen. J Korean Med Sci 2008; 23:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/34\">",
"      Micozzi MS, Pribitkin EA. Common herbal remedies, adverse reactions, and dermatologic effects. Skinmed 2010; 8:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/35\">",
"      Caiozzi G, Cabrera D, Mard&oacute;nez JM, Sald&iacute;as F. [Herbal medicines and severe adverse effects: uvular angioedema caused by Echballium elaterium]. Rev Med Chil 2002; 130:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/36\">",
"      Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/37\">",
"      Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/38\">",
"      Gleich GJ, Schroeter AL, Marcoux JP, et al. Episodic angioedema associated with eosinophilia. N Engl J Med 1984; 310:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/39\">",
"      Lassalle P, Gosset P, Gruart V, et al. Presence of antibodies against endothelial cells in the sera of patients with episodic angioedema and hypereosinophilia. Clin Exp Immunol 1990; 82:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/40\">",
"      Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007; 27:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/41\">",
"      Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006; 30:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/42\">",
"      Nakashima K, Sakurada T, Imayama S, et al. A case of episodic angioedema associated with blood eosinophilia: upregulated C5a receptor expression on eosinophils. Allergy 1998; 53:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/43\">",
"      Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Allergy Immunol 2002; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38391/abstract/44\">",
"      Jara LJ, Navarro C, Medina G, et al. Hypocomplementemic urticarial vasculitis syndrome. Curr Rheumatol Rep 2009; 11:410.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8099 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38391=[""].join("\n");
var outline_f37_31_38391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mast cell-mediated etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Direct mast cell release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Aspirin and NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chronic urticaria with or without angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bradykinin-mediated etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hereditary and acquired angioedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Estrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Etiologies of unknown mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Idiopathic angioedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Fibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18165957\">",
"      - Herbal medicines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other rare causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8099|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/45/21213\" title=\"figure 1\">",
"      ACEI v ARBs in AE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8099|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/8/11403\" title=\"table 1\">",
"      Mast cell mediated angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/11/13500\" title=\"table 2\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37465?source=related_link\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26824?source=related_link\">",
"      Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/31/1523?source=related_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38392="Vanishing white matter disease";
var content_f37_31_38392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vanishing white matter disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Amy T Waldman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38392/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/31/38392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vanishing white matter disease (VWM; MIM #603896), also known as childhood ataxia with central nervous system hypomyelination, leukoencephalopathy with vanishing white matter, and Cree leukoencephalopathy, is a chronic and progressive white matter disorder, often exacerbated by infection or head trauma.",
"   </p>",
"   <p>",
"    Scattered neuropathologic case reports beginning in the 1960s were the earliest descriptions of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. In 1988, a study from Canada described a severe infantile leukodystrophy in three Cree Indian villages termed \"Cree leukoencephalopathy\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/9\">",
"     9",
"    </a>",
"    ], a condition that is now recognized as a phenotypic variant of VWM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10\">",
"     10",
"    </a>",
"    ]. However, VWM was not recognized as a clinical syndrome until the 1990s.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 1993 study from Germany described three children with normal early development who rapidly declined with progressive ataxia and spasticity, followed later by bulbar symptoms, optic atrophy, and seizures; brain magnetic resonance imaging (MRI) showed a diffuse hypodensity of the white matter similar to the signal of the ventricles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1994 report from the United States described four unrelated patients with progressive ataxic diplegia that was named \"childhood ataxia with diffuse central nervous system hypomyelination\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1997, a study from the Netherlands described a cohort of nine children, including three affected sibling pairs, who had similar clinical, radiographic, and pathologic characteristics and were diagnosed with a \"new leukoencephalopathy with vanishing white matter\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Later studies have revealed the genetic underpinnings and the phenotypic variability of VWM, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance of VWM is autosomal recessive. Mutations in any of the five genes that encode subunits of the eukaryotic translation initiation factor eIF2B are the cause of VWM and its phenotypic variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10,14\">",
"     10,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The eIF2B protein complex is composed of five different subunits (eIF2Balpha, eIF2Bbeta, eIF2Bgamma, eIF2Bdelta, and eIF2Bepsilon). The genes corresponding to these subunits are named EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5 and are located on chromosomes 12q24.3, 14q24, 1p34.1, 2p23.3, and 3q27, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eukaryotic initiation factors are involved in the translation of mRNA to polypeptides. A general discussion of translation is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The eIF2B protein complex plays a critical role in the initiation of protein synthesis and the cellular response to stress by activating the initiation factor eIF2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. In this role, eIF2B catalyzes the exchange of guanosine diphosphate (GDP), which is bound to inactive eIF2, for guanosine triphosphate (GTP). Activated eIF2-GTP delivers the initiator methionyl-transfer RNA (Met-tRNA) to the small ribosomal subunits. Upon recognition of the start codon of the RNA, the GTP bound to eIF2 is hydrolyzed to GDP, which renders eIF2 inactive. To begin another round of protein synthesis, eIF2B must reactivate eIF2 by exchanging GDP for GTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During periods of stress, RNA translation is normally inhibited in order to conserve cellular energy and increase cellular survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/16\">",
"     16",
"    </a>",
"    ]. The cellular stress response can be triggered by various conditions, such as trauma, heat, and infection. Cellular stress causes the misfolding of proteins, which can lead to apoptosis of the cell by activating the unfolded protein response in the endoplasmic reticulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, hyperthermia causes protein denaturation, which can also activate the unfolded protein response and apoptosis.",
"   </p>",
"   <p>",
"    Mutations in one of the five causative genes (EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5) result in decreased activity of eIF2B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], but it is uncertain how this reduced activity leads to disease in VWM. However, it is likely that the decreased activity of eIF2B disrupts the cellular response to stress and causes inappropriate activation of the unfolded protein response, which would explain the association of VWM-related disease onset",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rapid deterioration with stress, injury, or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. In addition, glial cells appear to have a selective vulnerability to decreased eIF2B activity, which explains the predominant involvement of white matter in the brain as seen in VWM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,20\">",
"     8,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise incidence and prevalence of VWM is unknown, but it may be one of the more common leukodystrophies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ]. Among patients with a leukodystrophy of unknown etiology, one review stated that 40 percent met clinical criteria for VWM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/21\">",
"     21",
"    </a>",
"    ], and a report of 92 patients with leukoencephalopathy of unknown origin found radiographic features of VWM by MRI in 21 (23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/22\">",
"     22",
"    </a>",
"    ]. At the time of these studies, the genetic mutations now implicated in VWM were not completely defined.",
"   </p>",
"   <p>",
"    In a study of 50 unaffected Cree adults, 1 in 10 adults were heterozygous for a G584A mutation on the EIF2B5 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10\">",
"     10",
"    </a>",
"    ], suggesting a high carrier rate in select populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical features of VWM are progressive neurologic deterioration with prominent ataxia and spasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Optic atrophy and seizures can occur. Intellectual functioning is usually relatively spared. Febrile illness, minor head trauma, or severe fright often leads to sudden neurologic deterioration, including coma, with incomplete recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13,23,24\">",
"     13,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are now five clinical subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antenatal",
"     </li>",
"     <li>",
"      Infantile",
"     </li>",
"     <li>",
"      Early childhood",
"     </li>",
"     <li>",
"      Late",
"      <span class=\"nowrap\">",
"       childhood/juvenile",
"      </span>",
"     </li>",
"     <li>",
"      Adult (over 15 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with an earlier age of onset have a more severe form of VWM with more rapid decline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antenatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antenatal form presents in the third trimester with decreased fetal movements and oligohydramnios. At birth, affected neonates have feeding difficulties, hypotonia, and microcephaly. Renal hypoplasia and contractures are present, likely related to the decreased amniotic fluid.",
"   </p>",
"   <p>",
"    In this variant, systemic involvement is most pronounced. Growth failure, cataracts, pancreatitis, hepatosplenomegaly, and ovarian dysgenesis may be found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients develop intractable epilepsy, apneic spells, and coma. Affected infants die before the age of one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infantile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infantile form of VWM is a severe type that presents in the first year of life. Reported cases are few, but onset in the first year of life was seen in two infants who developed irritability and stupor with a rapid decline in motor abilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rapidly progressive infantile-onset form of VWM was first described in Native Indian infants in northern Quebec and Manitoba and designated \"Cree leukoencephalopathy\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/9\">",
"     9",
"    </a>",
"    ]. These infants presented with hypotonia, followed by seizures between three and six months of age, and progressive disease characterized by lethargy, spasticity, developmental regression, and cessation of head growth; death occurred by two years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early childhood form of VWM is the most common variant and presents between one and five years of age. This form is characterized by the classic phenotype of cerebellar ataxia with less prominent spasticity and little if any cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. As noted above, seizures and optic atrophy with visual loss may also occur. Most affected children die within a few years after onset, although some have lived only a few months, while others have survived for several decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/11-13,23\">",
"     11-13,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Late childhood/juvenile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The late",
"    <span class=\"nowrap\">",
"     childhood/juvenile",
"    </span>",
"    form presents between 5 and 15 years. The course is usually more slowly progressive than earlier-onset forms of VWM, with spastic diplegia, relative sparing of mentation, and typically (but not always) with longer survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adult",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult form is characterized by the same neurologic findings as childhood and juvenile forms but with greater spasticity than ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. In general, the course may be milder than younger-onset forms of VWM, but it is still progressive. Coma is less frequent than in children.",
"   </p>",
"   <p>",
"    In the largest adult series, 16 patients from 14 families with EIF2B mutations were followed for a mean of 11 years (range 2-22 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/31\">",
"     31",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age of onset was 31 years (range 16&ndash;62 years).",
"     </li>",
"     <li>",
"      The initial manifestations were neurologic (predominantly gait disturbance with spastic paraparesis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cerebellar ataxia) in 11 patients, psychiatric (depression and schizophrenia) in two, and endocrine (ovarian failure) in two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/31\">",
"       31",
"      </a>",
"      ]. One family member was asymptomatic when diagnosed at age 16.",
"     </li>",
"     <li>",
"      Brain MRI findings included cerebral atrophy in all 16 patients, cystic leukoencephalopathy in 13, and cerebellar atrophy in 12.",
"     </li>",
"     <li>",
"      Stress-induced deterioration at onset or during the course of the disease was reported for six patients, including precipitation of death in two. One death occurred after a minor head trauma led to irreversible brain edema, and the other after a generalized seizure led to intractable status epilepticus.",
"     </li>",
"     <li>",
"      Among the 14 survivors, disease evolution was progressive in all but three, with loss of independent ambulation in 11 (including three who became bedridden) at a mean age of 47 years (range 16 to 62 years) and cognitive decline in eight. One patient remained asymptomatic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smaller studies in adults have also reported mental decline, dementia, epilepsy, psychotic symptoms, and deterioration with illness and trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/27,28,30,32,33\">",
"     27,28,30,32,33",
"    </a>",
"    ]. In one series of five patients with onset of VWM between 14 and 45 years, the time to death ranged from a few months to 14 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ovarioleukodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outside of the brain, the ovaries are the most frequently affected organs in females with VWM, and primary or secondary ovarian failure is a common finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,13,25,34-36\">",
"     8,13,25,34-36",
"    </a>",
"    ]. Vanishing white matter disease with ovarian failure is also known as ovarioleukodystrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenotypic heterogeneity of VWM has been observed among members of the same family and among individuals with the same mutation, suggesting that the phenotype is influenced by the environment and perhaps by other genetic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. However, certain genotype-phenotype correlations have been described, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent mutation, a 338G&gt;A nucleotide substitution (p.Arg113His) in EIF2B5, is the mildest. EIF2B5 mutations homozygous for p.Arg113His typically are associated with adult-onset type VWM and slow disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/28,37\">",
"       28,37",
"      </a>",
"      ], and have never been associated with the infantile subtype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, patients homozygous for the p.Arg113His substitution have a milder phenotype than those who are compound heterozygous for p.Arg113His [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A milder clinical course (ie, late onset and slow progression) has also been associated with the 638A&gt;G mutation (p.Glu213Gly) in EIF2B2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A homozygous 584G&gt;A missense mutation in exon 4 of EIF2B5, resulting in a p.Arg195His substitution of eIF2Bepsilon, was identified in patients with Cree leukoencephalopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10\">",
"       10",
"      </a>",
"      ] and is always associated with early onset and short survival.",
"     </li>",
"     <li>",
"      Ovarioleukodystrophy (ie, VWM and ovarian failure) is caused by mutations in EIF2B2, EIF2B4, and EIF2B5 genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 925G&gt;C mutation (p.Val309Leu) in EIF2B5 is associated with increased disease severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/17,20\">",
"       17,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the cerebral white matter \"vanishes\" over time, the MRI signal changes from high to low intensity on proton density and fluid-attenuated inversion recovery (FLAIR) sequences due to the progressive replacement of the white matter by cerebrospinal fluid, leaving only a meshwork of strands in the abnormal white matter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50611 \" href=\"mobipreview.htm?35/19/36145\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. Proton density and FLAIR MRI sequences are best able to differentiate between white matter that is rarefied, with high to intermediate signal intensity, or cystic, with low signal intensity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69349 \" href=\"mobipreview.htm?19/38/20074\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56166 \" href=\"mobipreview.htm?18/35/18996\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/39\">",
"     39",
"    </a>",
"    ]. Diffusion-weighted imaging shows increased diffusion in areas of rarefied or cystic white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/40\">",
"     40",
"    </a>",
"    ]. Restricted diffusion has been observed in several relatively spared brain regions (ie, cortical U fibers, cerebellar white matter, middle cerebral peduncles, pyramidal tracts, corpus callosum, and posterior limb of the internal capsule), predominantly in younger patients with a shorter disease duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/41\">",
"     41",
"    </a>",
"    ]. Contrast enhancement has not been reported in VWM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In late stages of VWM, the cerebral white matter is diffusely abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/42\">",
"     42",
"    </a>",
"    ], approaching the intensity of cerebrospinal fluid on all MRI sequences, with low signal on T1-weighted images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50611 \" href=\"mobipreview.htm?35/19/36145\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69349 \" href=\"mobipreview.htm?19/38/20074\">",
"     image 3",
"    </a>",
"    ) and high signal on T2-weighted, FLAIR, and proton density images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. As noted above, a meshwork of strands may be seen radiating through the rarefied and cystic abnormal white matter on T1-weighted, FLAIR, and proton density MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13,23\">",
"     13,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, the cortical gyri may appear swollen and slightly broader than normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cerebellum and brainstem are generally spared by the process of white matter rarefaction and cystic degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,13,23\">",
"     8,13,23",
"    </a>",
"    ]. However, MRI signal abnormalities may occur in the brainstem, which may undergo some degree of atrophy over time (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"     image 1",
"    </a>",
"    ). Mild to severe cerebellar atrophy, especially involving the vermis, may also be seen.",
"   </p>",
"   <p>",
"    In the antenatal and early infantile VWM, the brain MRI may initially show only features of immaturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,25,36\">",
"     8,25,36",
"    </a>",
"    ]. As the disease progresses, the cerebral white matter may undergo the process of rarefaction and cystic atrophy. Unlike the later onset VWM variants, the white matter becomes severely atrophic in some cases of the antenatal variant.",
"   </p>",
"   <p>",
"    In parallel with the progressive loss of cerebral white matter, magnetic resonance spectroscopy (MRS) shows an increased loss over time of the normal N-acetylaspartate, choline, and creatine signals in the cerebral white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/11,13,21,23,43\">",
"     11,13,21,23,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the late stages of VWM, when cystic white matter and cerebrospinal fluid predominates, all normal metabolic peaks may be absent in the white matter on MRS. Furthermore, there are small additional peaks corresponding to lactate and to glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13\">",
"     13",
"    </a>",
"    ]. As lactate and glucose are present in cerebrospinal fluid, these findings confirm the replacement of cellular elements with cerebrospinal fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;At autopsy, gross sections of the brain demonstrate extensive cystic, gelatinous, or cavitary degeneration involving the periventricular and immediate subcortical white matter, with partial sparing of the U-fibers (",
"    <a class=\"graphic graphic_picture graphicRef82200 \" href=\"mobipreview.htm?2/1/2067\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,13,23,44-46\">",
"     8,13,23,44-46",
"    </a>",
"    ]. Symmetric brainstem lesions within the central tegmental tracts may be present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78840 \" href=\"mobipreview.htm?27/24/28037\">",
"     image 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopically, the white matter demonstrates marked rarefaction, severe loss of myelin with spongy degeneration, vacuolation, astrocytic gliosis, and macrophage proliferation in some areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13\">",
"     13",
"    </a>",
"    ]. Myelin loss is seen in the retrobulbar optic nerve in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oligodendrocyte abnormalities in VWM include both increased and decreased cell numbers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/47\">",
"     47",
"    </a>",
"    ], altered morphology, and apoptotic cell death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased density of oligodendrocytes may be seen in areas of preserved white matter in the cerebrum, cerebellum, and pons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/23,44,45,47\">",
"       23,44,45,47",
"      </a>",
"      ]. While one report interpreted this finding as an artifact caused by compaction of brain parenchyma during cell loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/45\">",
"       45",
"      </a>",
"      ], a later case-control study observed statistically significant increases in oligodendrocyte densities in cases of VWM compared with age-matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal foamy oligodendroglial cells, characterized by abundant cytoplasm, mitochondria filled with circular, membranous structures, and the absence of lysosomes, are pathognomonic for VWM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced numbers of oligodendrocytes are seen in areas of cavitary white matter degeneration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13,46\">",
"       13,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apoptotic labeling of oligodendrocytes has been observed in some patients, particularly those with early-onset severe VWM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is thought that oligodendrocytes are exposed to conflicting proliferative, proapoptotic, and prosurvival signals during the course of VWM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/15,47\">",
"     15,47",
"    </a>",
"    ]. Oligodendrocyte apoptosis may occur particularly during periods of neurologic crises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/47\">",
"     47",
"    </a>",
"    ]. However, some oligodendrocytes are able to persist and proliferate, particularly in patients with later-onset and less severe VWM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of VWM is supported when MRI criteria are fulfilled in patients who have the typical clinical and MRI features of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8,20\">",
"     8,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'MRI criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Genetic testing using sequence analysis or mutation scanning is clinically available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ] and is suggested to confirm the diagnosis of VWM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     MRI criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proposed obligatory MRI criteria for the diagnosis of VWM are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are diffuse or extensive signal abnormalities involving the cerebral white matter; the adjacent subcortical white matter may be spared (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50611 \" href=\"mobipreview.htm?35/19/36145\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69349 \" href=\"mobipreview.htm?19/38/20074\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56166 \" href=\"mobipreview.htm?18/35/18996\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Part or all of the abnormal white matter has a signal intensity close to or the same as cerebrospinal fluid on proton density or fluid-attenuated inversion recovery (FLAIR) images",
"     </li>",
"     <li>",
"      There is a fluid-filled space (not a total collapse of the white matter) between the ependymal lining and the cortex if proton density and FLAIR images suggest that all cerebral white matter has disappeared",
"     </li>",
"     <li>",
"      The disappearance of the cerebral white matter occurs in a diffuse \"melting away\" pattern (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The temporal lobes are relatively spared in the extent of the abnormal signal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      degree of cystic destruction",
"     </li>",
"     <li>",
"      The cerebellar white matter may be abnormal, but does not contain cysts",
"     </li>",
"     <li>",
"      There is no contrast enhancement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proposed suggestive MRI criteria for the diagnosis of VWM are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pattern of radiating stripes within abnormal white matter is seen on sagittal and coronal T1-weighted or FLAIR images; dots and stripes are seen within the abnormal white matter on axial images, representing cross-sections of the stripes seen on sagittal and coronal images (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      There are lesions within the central tegmental tracts in the pontine tegmentum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      There is involvement of the inner rim of the corpus callosum, with sparing of the outer rim",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These MRI criteria are NOT useful in infants with the antenatal and early infantile forms of VWM, or in patients of any age with very early disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ]. In such cases, genetic confirmation of VWM is essential to establish the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of individuals diagnosed by clinical and MRI criteria have mutations in one of the five causative genes (EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ]. More than 120 mutations of EIF2B genes have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/48\">",
"     48",
"    </a>",
"    ]. Mutations in the EIF2B5 gene account for more than one-half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing may be particularly important to establish the diagnosis of VWM in patients with neonatal or early infantile-onset variants, as brain MRI features in early-onset disease may be atypical and are unlikely to meet MRI criteria for VWM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests are generally normal in patients with VWM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ]. Standard cerebrospinal fluid (CSF) analysis is likewise normal.",
"   </p>",
"   <p>",
"    A reduced CSF",
"    <span class=\"nowrap\">",
"     asialotransferrin/total",
"    </span>",
"    transferrin ratio, as determined by two-dimensional gel electrophoresis, may be a useful biomarker for the identification of patients with eIF2B mutations. In a sample of six patients with VWM and confirmed eIF2B mutations who were compared with 54 controls (including six patients with a clinical presentation consistent with VWM but no eIF2B mutations), an",
"    <span class=\"nowrap\">",
"     asialotransferrin/transferrin",
"    </span>",
"    ratio of &lt;8 percent had a sensitivity and specificity of 100 and 94 percent, respectively, for the identification of patients with eIF2B mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the test is inexpensive and rapid (&lt;48 hours), the investigators suggested that determination of",
"    <span class=\"nowrap\">",
"     asialotransferrin/transferrin",
"    </span>",
"    ratio could be used to screen cases with a suspected diagnosis of VWM prior to genetic mutation analysis, which can take weeks to months before results are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the data set included no patients with neonatal or infantile onset, and further confirmation is needed to determine if the test is useful in these subgroups.",
"   </p>",
"   <p>",
"    Currently, determination of the",
"    <span class=\"nowrap\">",
"     asialotransferrin/transferrin",
"    </span>",
"    ratio by two-dimensional gel electrophoresis is available only on a research basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of VWM includes two conditions associated with rapid neurologic deterioration following a febrile infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ], namely acute disseminated encephalomyelitis (ADEM) and encephalitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ADEM should be suspected in a child with fever and neurologic abnormalities, including impaired consciousness, especially one to two weeks after a viral infection. Unlike VWM, most children with ADEM present with meningeal signs and acute encephalopathy along with evidence of inflammation in blood and cerebrospinal fluid. MRI of the brain and spinal cord typically shows asymmetric multifocal white matter abnormalities, best defined by T2-weighted and FLAIR sequences. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/52/25416?source=see_link\">",
"       \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Encephalitis is a febrile illness with signs and symptoms of neurologic dysfunction (eg, cranial nerve palsies, seizures, paralysis, dysarthria)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      altered state of consciousness related to parenchymal brain involvement. MRI of the brain may show lesions of white and gray matter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contrast enhancement and restricted diffusion are typical MRI features of encephalitis and ADEM, but not of VWM.",
"   </p>",
"   <p>",
"    The differential diagnosis of VWM also includes inherited disorders presenting in infancy and childhood with progressive neurologic deterioration and diffuse white matter abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitochondrial disorders (eg, pyruvate dehydrogenase deficiency and pyruvate carboxylase deficiency) can cause leukoencephalopathy with diffuse rarefaction and cystic degeneration of white matter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alexander disease causes variable symptoms depending on age, such as megalencephaly, psychomotor retardation, pseudobulbar signs, spasticity, and ataxia, with progressive deterioration. Serial MRI scans demonstrate increasing frontoparietal white matter atrophy with cystic degeneration. Unlike VWM, contrast enhancement of selected gray and white matter structures is characteristic of Alexander disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40872?source=see_link\">",
"       \"Alexander disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Megalencephalic leukoencephalopathy with subcortical cysts (MLC) presents with macrocephaly in the first year of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. Other symptoms include mild developmental delay, ataxia, spasticity, and seizures. Cognition is relatively spared. The disorder is caused by mutations in the MLC1 and HEPACAM genes. Unlike VWM, the cerebral white matter does not undergo diffuse rarefaction and cystic degeneration in MLC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/20\">",
"       20",
"      </a>",
"      ]. However, the MRI does show diffuse supratentorial white matter abnormalities in patients with MLC, and cystic brain lesions are seen, mostly in the frontoparietal border zone region and anterior-temporal subcortical white matter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other leukodystrophies, such as adrenoleukodystrophy, metachromatic leukodystrophy, Krabbe disease, and Pelizaeus-Merzbacher disease, are likewise not associated with diffuse cystic cerebral white matter degeneration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4038?source=see_link\">",
"     \"Krabbe disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/27/42421?source=see_link\">",
"     \"Metachromatic leukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13465?source=see_link\">",
"     \"Pelizaeus-Merzbacher disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ovarian dysfunction has not been identified in any leukoencephalopathy other than VWM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no cure or specific treatment for VWM.",
"   </p>",
"   <p>",
"    Avoidance of stressful situations that may trigger deterioration in VWM is crucial to the management, even though such measures are insufficient to prevent VWM onset and progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ]. Since even minor head trauma can lead to worsening, contact sports should be avoided. Since infection and fever can have deleterious effects, antibiotics and antipyretics should be used liberally, and vaccinations, such as the influenza vaccine, should be kept up-to-date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical therapy, rehabilitation, and antispasmodic medications can be used to improve the gait and tone.",
"   </p>",
"   <p>",
"    Antiepileptic drugs are used in patients with epilepsy. The management of seizures and epilepsy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vanishing white matter disease (VWM; MIM #603896) is a chronic and progressive white matter disorder, often exacerbated by infection or head trauma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in any of the five genes (EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5) that encode subunits of the eukaryotic translation initiation factor eIF2B are the cause of VWM and its phenotypic variants. These mutations result in decreased activity of eIF2B, which is thought to disrupt the cellular response to stress. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precise incidence and prevalence of VWM is unknown, but it may be one of the more common leukodystrophies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are five clinical subtypes (antenatal, infantile, early childhood, late",
"      <span class=\"nowrap\">",
"       childhood/juvenile,",
"      </span>",
"      and adult) of VWM by age of onset. Patients with an earlier age of onset have a more rapid decline. In the early childhood variant, which is the most common, the major clinical features of VWM are progressive neurologic deterioration with prominent ataxia and spasticity. Optic atrophy and seizures can occur. Intellectual functioning is usually relatively spared. Febrile illness, minor head trauma, or severe fright often lead to sudden neurologic deterioration, including coma, with incomplete recovery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The brain MRI signal of the cerebral white matter changes from high to low intensity on proton density and FLAIR sequences as the white matter \"vanishes\" over time and is progressively replaced by cerebrospinal fluid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81055 \" href=\"mobipreview.htm?34/30/35299\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50611 \" href=\"mobipreview.htm?35/19/36145\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69349 \" href=\"mobipreview.htm?19/38/20074\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56166 \" href=\"mobipreview.htm?18/35/18996\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At autopsy, gross sections of the brain demonstrate extensive cystic, gelatinous, or cavitary degeneration involving the periventricular and immediate subcortical white matter (",
"      <a class=\"graphic graphic_picture graphicRef82200 \" href=\"mobipreview.htm?2/1/2067\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of VWM can be confirmed by MRI criteria in patients who have the typical clinical and MRI features of the disease. Genetic testing is suggested to confirm the diagnosis of VWM, particularly in cases with atypical MRI findings. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no cure or specific treatment for VWM. Avoidance of stressful situations that may trigger deterioration in VWM is important. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/1\">",
"      Eicke WJ. Polycystische umwandlung des marklagers mit progredientem verlauf. Atypische diffuse sklerose? Arch Psychiat Nervenkr 1962; 203:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/2\">",
"      Watanabe I, Muller J. Cavitating \"diffuse sclerosis\". J Neuropathol Exp Neurol 1967; 26:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/3\">",
"      Girard PF, Tommasi M, Rochet M, Boucher M. [Leukoencephalopathy with large bilateral symmetrical cavitation. Post-traumatic decortication syndrome]. Presse Med 1968; 76:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/4\">",
"      Anzil AP, Gessaga E. Late-life cavitating dystrophy of the cerebral and cerebellar white matter. A form of sudanophil leucodystrophy. Eur Neurol 1972; 7:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/5\">",
"      Deisenhammer E, Jellinger K. [Cavitating neutral fat leukodystrophy with recurrent course]. Neuropadiatrie 1976; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/6\">",
"      Gautier JC, Gray F, Awada A, Escourolle R. [Cavitary orthochromatic leukodystrophy in the adult. Oligodendroglial proliferation and inclusions]. Rev Neurol (Paris) 1984; 140:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/7\">",
"      Graveleau P, Gray F, Plas J, et al. [Cavitary orthochromatic leukodystrophy with oligodendroglial changes. A sporadic adult case]. Rev Neurol (Paris) 1985; 141:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/8\">",
"      van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter disease. Lancet Neurol 2006; 5:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/9\">",
"      Black DN, Booth F, Watters GV, et al. Leukoencephalopathy among native Indian infants in northern Quebec and Manitoba. Ann Neurol 1988; 24:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/10\">",
"      Fogli A, Wong K, Eymard-Pierre E, et al. Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus. Ann Neurol 2002; 52:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/11\">",
"      Hanefeld F, Holzbach U, Kruse B, et al. Diffuse white matter disease in three children: an encephalopathy with unique features on magnetic resonance imaging and proton magnetic resonance spectroscopy. Neuropediatrics 1993; 24:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/12\">",
"      Schiffmann R, Moller JR, Trapp BD, et al. Childhood ataxia with diffuse central nervous system hypomyelination. Ann Neurol 1994; 35:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/13\">",
"      van der Knaap MS, Barth PG, Gabre&euml;ls FJ, et al. A new leukoencephalopathy with vanishing white matter. Neurology 1997; 48:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/14\">",
"      Ohlenbusch A, Henneke M, Brockmann K, et al. Identification of ten novel mutations in patients with eIF2B-related disorders. Hum Mutat 2005; 25:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/15\">",
"      van der Voorn JP, van Kollenburg B, Bertrand G, et al. The unfolded protein response in vanishing white matter disease. J Neuropathol Exp Neurol 2005; 64:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/16\">",
"      Welch WJ. Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 1992; 72:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/17\">",
"      Li W, Wang X, Van Der Knaap MS, Proud CG. Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways. Mol Cell Biol 2004; 24:3295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/18\">",
"      Fogli A, Schiffmann R, Hugendubler L, et al. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. Eur J Hum Genet 2004; 12:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/19\">",
"      Leegwater PA, Vermeulen G, K&ouml;nst AA, et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet 2001; 29:383.",
"     </a>",
"    </li>",
"    <li>",
"     Schiffmann R, Fogli A, van der Knaap MS, Boespflug-Tanguy O. Childhood ataxia with central nervous system hypomyelination/vanishing white matter. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1258/ (Accessed on February 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/21\">",
"      Schiffmann R, Boespfl&uuml;g-Tanguy O. An update on the leukodsytrophies. Curr Opin Neurol 2001; 14:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/22\">",
"      van der Knaap MS, Breiter SN, Naidu S, et al. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology 1999; 213:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/23\">",
"      van der Knaap MS, Kamphorst W, Barth PG, et al. Phenotypic variation in leukoencephalopathy with vanishing white matter. Neurology 1998; 51:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/24\">",
"      Vermeulen G, Seidl R, Mercimek-Mahmutoglu S, et al. Fright is a provoking factor in vanishing white matter disease. Ann Neurol 2005; 57:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/25\">",
"      van der Knaap MS, van Berkel CG, Herms J, et al. eIF2B-related disorders: antenatal onset and involvement of multiple organs. Am J Hum Genet 2003; 73:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/26\">",
"      Francalanci P, Eymard-Pierre E, Dionisi-Vici C, et al. Fatal infantile leukodystrophy: a severe variant of CACH/VWM syndrome, allelic to chromosome 3q27. Neurology 2001; 57:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/27\">",
"      Gallo A, Rocca MA, Falini A, et al. Multiparametric MRI in a patient with adult-onset leukoencephalopathy with vanishing white matter. Neurology 2004; 62:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/28\">",
"      van der Knaap MS, Leegwater PA, van Berkel CG, et al. Arg113His mutation in eIF2Bepsilon as cause of leukoencephalopathy in adults. Neurology 2004; 62:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/29\">",
"      Ohtake H, Shimohata T, Terajima K, et al. Adult-onset leukoencephalopathy with vanishing white matter with a missense mutation in EIF2B5. Neurology 2004; 62:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/30\">",
"      Denier C, Orgibet A, Roffi F, et al. Adult-onset vanishing white matter leukoencephalopathy presenting as psychosis. Neurology 2007; 68:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/31\">",
"      Labauge P, Horzinski L, Ayrignac X, et al. Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. Brain 2009; 132:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/32\">",
"      Jansen AC, Andermann E, Niel F, et al. Leucoencephalopathy with vanishing white matter may cause progressive myoclonus epilepsy. Epilepsia 2008; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/33\">",
"      Biancheri R, Rossi A, Di Rocco M, et al. Leukoencephalopathy with vanishing white matter:: an adult onset case. Neurology 2003; 61:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/34\">",
"      Schiffmann R, Tedeschi G, Kinkel RP, et al. Leukodystrophy in patients with ovarian dysgenesis. Ann Neurol 1997; 41:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/35\">",
"      Fogli A, Rodriguez D, Eymard-Pierre E, et al. Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet 2003; 72:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/36\">",
"      Boltshauser E, Barth PG, Troost D, et al. \"Vanishing white matter\" and ovarian dysgenesis in an infant with cerebro-oculo-facio-skeletal phenotype. Neuropediatrics 2002; 33:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/37\">",
"      Fogli A, Schiffmann R, Bertini E, et al. The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology 2004; 62:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/38\">",
"      van der Lei HD, van Berkel CG, van Wieringen WN, et al. Genotype-phenotype correlation in vanishing white matter disease. Neurology 2010; 75:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/39\">",
"      Leegwater PA, Pronk JC, van der Knaap MS. Leukoencephalopathy with vanishing white matter: from magnetic resonance imaging pattern to five genes. J Child Neurol 2003; 18:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/40\">",
"      Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol 2005; 15:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/41\">",
"      van der Lei HD, Steenweg ME, Bugiani M, et al. Restricted diffusion in vanishing white matter. Arch Neurol 2012; 69:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/42\">",
"      Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/43\">",
"      Tedeschi G, Schiffmann R, Barton NW, et al. Proton magnetic resonance spectroscopic imaging in childhood ataxia with diffuse central nervous system hypomyelination. Neurology 1995; 45:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/44\">",
"      Rodriguez D, Gelot A, della Gaspera B, et al. Increased density of oligodendrocytes in childhood ataxia with diffuse central hypomyelination (CACH) syndrome: neuropathological and biochemical study of two cases. Acta Neuropathol 1999; 97:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/45\">",
"      Wong K, Armstrong RC, Gyure KA, et al. Foamy cells with oligodendroglial phenotype in childhood ataxia with diffuse central nervous system hypomyelination syndrome. Acta Neuropathol 2000; 100:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/46\">",
"      Br&uuml;ck W, Herms J, Brockmann K, et al. Myelinopathia centralis diffusa (vanishing white matter disease): evidence of apoptotic oligodendrocyte degeneration in early lesion development. Ann Neurol 2001; 50:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/47\">",
"      Van Haren K, van der Voorn JP, Peterson DR, et al. The life and death of oligodendrocytes in vanishing white matter disease. J Neuropathol Exp Neurol 2004; 63:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/48\">",
"      Maletkovic J, Schiffmann R, Gorospe JR, et al. Genetic and clinical heterogeneity in eIF2B-related disorder. J Child Neurol 2008; 23:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/49\">",
"      Pronk JC, van Kollenburg B, Scheper GC, van der Knaap MS. Vanishing white matter disease: a review with focus on its genetics. Ment Retard Dev Disabil Res Rev 2006; 12:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/50\">",
"      Vanderver A, Hathout Y, Maletkovic J, et al. Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder. Neurology 2008; 70:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/51\">",
"      de Lonlay-Debeney P, von Kleist-Retzow JC, Hertz-Pannier L, et al. Cerebral white matter disease in children may be caused by mitochondrial respiratory chain deficiency. J Pediatr 2000; 136:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/52\">",
"      Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, et al. White matter involvement in mitochondrial diseases. Mol Genet Metab 2005; 84:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/53\">",
"      van der Knaap MS, Barth PG, Stroink H, et al. Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol 1995; 37:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38392/abstract/54\">",
"      van der Knaap MS, Boor I, Est&eacute;vez R. Megalencephalic leukoencephalopathy with subcortical cysts: chronic white matter oedema due to a defect in brain ion and water homoeostasis. Lancet Neurol 2012; 11:973.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1701 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-109.224.62.197-08224556E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38392=[""].join("\n");
var outline_f37_31_38392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antenatal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infantile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Late childhood/juvenile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ovarioleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genotype-phenotype correlations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MRI criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1701\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1701|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/30/35299\" title=\"diagnostic image 1\">",
"      Brain MRI 16 year old vanishing white matter disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/19/36145\" title=\"diagnostic image 2\">",
"      Coronal brain MRI vanishing white matter disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/38/20074\" title=\"diagnostic image 3\">",
"      Brain MRI eIF2B mutated individuals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/35/18996\" title=\"diagnostic image 4\">",
"      Brain MRI adult vanishing white matter disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/24/28037\" title=\"diagnostic image 5\">",
"      Pontine lesions vanishing white matter disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1701|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/1/2067\" title=\"picture 1\">",
"      Neuropathology vanishing white matter disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40872?source=related_link\">",
"      Alexander disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/9/13465?source=related_link\">",
"      Pelizaeus-Merzbacher disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38393="NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity";
var content_f37_31_38393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     Shounak Das, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38393/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/31/38393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs), including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , cause considerable morbidity and mortality related to gastric and duodenal ulcer disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/1\">",
"     1",
"    </a>",
"    ]. In rheumatoid arthritis patients alone, it has been estimated that gastrointestinal (GI) toxicity related to NSAID use accounts for at least 2600 deaths in the United States annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, prevention of NSAID-induced GI damage is an important clinical issue.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    , proton pump inhibitors, and H2 receptor antagonists have been evaluated as prophylactic therapies for patients taking NSAIDs. In addition, the selective COX-2 inhibitors (coxibs) introduced a novel strategy for the prevention of NSAID-related gastroduodenal toxicity. However, the advantage of these coxibs over nonselective NSAIDs is debatable and cardiovascular toxicity has limited the use of coxibs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strategies for the primary prevention of gastroduodenal toxicity due to NSAIDs will be reviewed here. Emphasis will be placed upon studies that used clinically relevant end points (symptomatic ulcers and complicated ulcers, including bleeding, perforating, and obstructing ulcers). Studies using endoscopic detection of ulcers as the end point will be cited only when data on more meaningful clinical end points are lacking. The pathogenesis, treatment, and secondary prevention of NSAID-induced gastroduodenal injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26947?source=see_link\">",
"     \"NSAIDs (including aspirin): Treatment of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=see_link\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated factors for gastroduodenal toxicity from nonsteroidal antiinflammatory drugs (NSAIDs) and assessment of these risk factors is recommended for identifying patients who should be considered for prophylaxis if it is felt that an NSAID must be given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective study of osteoarthritis and rheumatoid arthritis patients aged &gt;49 randomized to either etoricoxib or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    use found the following factors to be significant predictors for gastrointestinal (GI) toxicity including bleeding, perforation, obstruction, or ulcer: age &gt;64, a history of prior events, or concurrent use of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to 2008 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    College of Gastroenterology",
"    <span class=\"nowrap\">",
"     (ACG)/American",
"    </span>",
"    Heart Association guidelines, patients are considered to be at high risk for GI toxicity from NSAIDs if they have a history of ulcer disease or complication, are on dual antiplatelet therapy, are on an NSAID with concomitant anticoagulant therapy, or have more than one risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;60 years",
"     </li>",
"     <li>",
"      Corticosteroid use",
"     </li>",
"     <li>",
"      Dyspepsia or gastroesophageal reflux disease (GERD) symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in 2009 guidelines from the ACG patients are instead classified as being at high, moderate, or low risk (",
"    <a class=\"graphic graphic_table graphicRef71256 \" href=\"mobipreview.htm?25/4/25675\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History of complicated peptic ulcer disease",
"     </li>",
"     <li>",
"      Multiple (&gt;2) risk factors (see below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate risk (1 to 2 risk factors)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      High dose NSAID therapy",
"     </li>",
"     <li>",
"      A previous history of an uncomplicated ulcer",
"     </li>",
"     <li>",
"      Concurrent use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (including low dose), corticosteroids, or anticoagulants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No risk factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of selective serotonin reuptake inhibitors (SSRIs) has also been associated with an increased risk of GI bleeding. A meta-analysis of observational studies showed an odds ratio of 2.36 (1.44-3.85) for SSRI associated upper GI hemorrhage. The odds ratio increased to 6.33 (3.40-11.8) for concurrent SSRI and NSAID use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link&amp;anchor=H11#H11\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Risk of gastrointestinal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, we follow the 2009 ACG guidelines when deciding which patients should receive prophylaxis with a proton pump inhibitor (PPI). However, it must be kept in mind that these are guidelines and not firm recommendations and that treatment decisions need to be individualized. In particular, for patients being considered for dual antiplatelet therapy, we take both sets of guidelines into account when determining whether a patient is high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NONSELECTIVE NSAIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies of varying design have described gastrointestinal (GI) toxicity of different nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/2,9-11\">",
"     2,9-11",
"    </a>",
"    ]. One study looked at 150 asymptomatic patients taking low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/12\">",
"     12",
"    </a>",
"    ]. The patients all underwent upper endoscopy. Ulcers were found in 4 percent and erosions in 34 percent.",
"   </p>",
"   <p>",
"    The following conclusions were reached in a meta-analysis of controlled trials involving some of the most commonly prescribed NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of gastrointestinal complications was highest with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (relative risk {RR} 2.25) followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (RR 1.83),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      (RR 1.73),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=see_link\">",
"       piroxicam",
"      </a>",
"      (RR 1.66), tenoxicam (RR 1.43),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (RR 1.43), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/38/35432?source=see_link\">",
"       meloxicam",
"      </a>",
"      (RR 1.24).",
"     </li>",
"     <li>",
"      The risk was related to the duration of treatment. The average duration of treatment before observing a significant risk of GI effects was 84 days. However, an increased risk was apparent as early as seven days with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar conclusions were reached in an earlier meta-analysis, which ranked the risk of various NSAIDs relative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , which at the time was considered to have the lowest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/10\">",
"     10",
"    </a>",
"    ]. A ranking of increasing risk was found in the following order: ibuprofen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/52/27464?source=see_link\">",
"     fenoprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/41/25240?source=see_link\">",
"     diflunisal",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33512?source=see_link\">",
"     tolmetin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    , and azapropazone.",
"   </p>",
"   <p>",
"    A cohort study conducted in United States veterans suggests that the NSAID",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/35/13881?source=see_link\">",
"     etodolac",
"    </a>",
"    caused significantly fewer clinically significant upper gastrointestinal events than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , an effect that was eliminated by concurrent treatment with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ulcer risk was also increased with higher doses of the NSAIDs in the aforementioned meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/13\">",
"     13",
"    </a>",
"    ]. The following relative risks were observed in a subset of five studies that had described GI toxicity relative to the dose of the NSAID:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (RR 1.6, 95% CI 0.8-3.2)",
"     </li>",
"     <li>",
"      High dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (RR 4.2, 95% CI 1.8-9.8)",
"     </li>",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (RR 3.7, 95% CI 1.7-7.7)",
"     </li>",
"     <li>",
"      High dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (RR 6.0, 95% CI 3.0-12.2)",
"     </li>",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (RR 3.0, 95% CI 2.2-4.2)",
"     </li>",
"     <li>",
"      High dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (RR 7.0, 95% CI 4.4-11.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the dosing cutoffs defining \"high\" versus \"low\" were somewhat arbitrary and varied across studies, they nevertheless support the observation that the risk associated with NSAIDs is related not only to the duration of therapy but also to the dose of treatment even within the low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    range (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H6#H6\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     Ketorolac",
"    </a>",
"    , which was not included in the above meta-analyses, is also associated with a high risk of GI toxicity, particularly when used in higher doses, in older patients, and for more than five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/15\">",
"     15",
"    </a>",
"    ]. One study found that ketorolac was 5.5 times more likely to cause GI toxicity than other NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/16\">",
"     16",
"    </a>",
"    ]. Because of the risks associated with ketorolac (both gastrointestinal and renal), its use is generally restricted to short-term pain treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENTERIC-COATED AND BUFFERED ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that a way to prevent gastrointestinal (GI) toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is the use of enteric-coated or buffered aspirin. Enteric-coated aspirin is designed to resist disintegration in the stomach, dissolving in the more neutral-to-alkaline environment of the duodenum.",
"   </p>",
"   <p>",
"    Although enteric-coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    diminishes endoscopic signs of gastroduodenal injury, it does not appear to protect against the clinically relevant end point of gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. These findings are not surprising, since injury severe enough to induce bleeding is thought to reflect the systemic rather than the topical effects of aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/23\">",
"     23",
"    </a>",
"    ]. The systemic effect of aspirin on the stomach and duodenum probably explains why buffered aspirin is no more effective than plain aspirin in preventing ulcer bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Systemic versus topical effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Low dose aspirin for cardiovascular protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to bleeding risk of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for secondary cardiovascular protection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H5#H5\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dual antiplatelet therapy (eg, aspirin and clopidogrel)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to GI bleeding with dual antiplatelet therapy in patients with cardiovascular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROLE OF HELICOBACTER PYLORI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the relationship between",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ) and the risk of peptic ulcer disease (PUD) in nonsteroidal antiinflammatory drug (NSAID) users. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Role of Helicobacter pylori infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the available evidence, the following is a reasonable approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of uncomplicated or complicated peptic ulcers (gastric, duodenal) should be tested for",
"      <em>",
"       H. pylori",
"      </em>",
"      prior to beginning a course of NSAID or low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy. If present,",
"      <em>",
"       H. pylori",
"      </em>",
"      should be treated with appropriate therapy, even if it is believed that the prior ulcer was due to NSAIDs.",
"     </li>",
"     <li>",
"      In asymptomatic patients with no history of ulcer and not currently taking an NSAID, physicians can consider",
"      <em>",
"       H. pylori",
"      </em>",
"      testing prior to beginning long-term therapy with a NSAID. A review of this topic suggested that eradication of",
"      <em>",
"       H. pylori",
"      </em>",
"      was beneficial in patients who were na&iuml;ve to NSAIDs, while little benefit was observed in patients already taking and tolerating NSAIDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/24\">",
"       24",
"      </a>",
"      ]. This \"test-and-treat\" approach may be more useful in populations with a relatively high prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SELECTIVE COX-2 INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary effect of nonsteroidal antiinflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (COX), thereby impairing the transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. Two related isoforms of COX exist: COX-1 and COX-2. COX-1 is involved in gastric and duodenal cytoprotection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/25\">",
"     25",
"    </a>",
"    ], while COX-2 is involved in inflammation and perhaps healing of gastroduodenal lesions. It has been proposed that the ideal NSAID would inhibit the inducible COX-2 isoform (thereby decreasing tissue inflammation) without having any effect on the constitutive COX-l isoform (thereby minimizing gastrointestinal [GI] toxicity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several major clinical trials have evaluated the efficacy and gastroduodenal toxicity of selective COX-2 inhibitors when compared to nonselective NSAIDs. Detailed information regarding these trials is presented elsewhere. These data suggest that COX-2 inhibitors are associated a reduced risk of gastrointestinal bleeding compared with nonselective NSAIDs but the risk is increased compared with placebo. Thus, COX-2 inhibitors may be safer than conventional NSAIDs for reduction in the risk of gastrointestinal bleeding but are still associated with an increased risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10375?source=see_link\">",
"     \"COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any potential gastroduodenal sparing effect with selective COX-2 inhibitors may be abrogated when they are used concurrently with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for primary or secondary prevention of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, patients receiving both aspirin and a selective COX-2 inhibitor may require prophylactic antiulcer therapy if they are at increased risk for gastroduodenal toxicity.",
"   </p>",
"   <p>",
"    A case-control trial suggested that patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    concomitantly with a selective COX-2 inhibitor have an increased risk of hospitalization for upper gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/28\">",
"     28",
"    </a>",
"    ]. The magnitude of risk was similar to the risk in anticoagulated patients taking nonselective NSAIDs, suggesting that the COX-2 inhibitors may not be protective in this population.",
"   </p>",
"   <p>",
"    Whether COX-2 inhibitors have led to a net benefit in terms of bleeding reduction from a population perspective is uncertain. Their introduction has led to increased use of these agents in the general population and thus has increased the absolute number of patients at risk for adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, these usage trends have changed with concerns related to cardiovascular toxicity.",
"   </p>",
"   <p>",
"    A population-based case control study found that the COX-2 inhibitors were associated with a modest reduction in the risk of gastrointestinal bleeding compared with nonselective NSAIDs (RR 0.6, 95% CI 0.4-0.9 among",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    nonusers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the safety profile for an individual drug was also related to its daily dose and plasma drug exposure. Furthermore, concomitant use of aspirin negated the benefit of the COX-2 inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some and perhaps all of the coxibs have been associated with an increased risk of stroke and myocardial infarction (MI). As a result, the use of these drugs has fallen markedly and some are no longer available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for reducing the risk of gastroduodenal toxicity include (a) using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    or a proton pump inhibitor (PPI) together with a nonselective nonsteroidal antiinflammatory drug (NSAID) or (b) using a selective COX-2 inhibitor with or without a PPI. None of these approaches is universally effective and their cost-effectiveness is incompletely understood. Furthermore, the use of COX-2 inhibitors is decreasing because of concerns related to increased cardiovascular morbidity and mortality.",
"   </p>",
"   <p>",
"    Multiple studies have evaluated a variety of strategies for preventing ulcers in patients requiring NSAIDs. A meta-analysis of 112 randomized controlled trials found no evidence supporting the effectiveness of H2 receptor antagonists while the risk of symptomatic ulcers was significantly reduced by PPIs (relative risk [RR] 0.09, 95% CI 0.02-0.47),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (RR 0.36, 95% CI 0.02-0.65) and COX-2 inhibitors (RR 0.49, 95% CI 0.38-0.65) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following will summarize major clinical trials. Emphasis will be placed upon studies that used clinically relevant end points (symptomatic ulcers and complicated ulcers, including bleeding, perforating, and obstructing ulcers). Studies using endoscopic detection of ulcers as the end point will be cited only when data on more meaningful clinical end points are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for NSAID-induced gastric or duodenal ulcer can be decreased with concomitant use of the prostaglandin E analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . In the largest trial, 8843 patients with rheumatoid arthritis receiving continuous therapy with any of 10 NSAIDs were randomly assigned to receive 200 &micro;g of misoprostol or placebo four times daily for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/3\">",
"     3",
"    </a>",
"    ]. Serious upper gastrointestinal (GI) complications (bleeding, perforation, gastric outlet obstruction) were reduced in patients receiving misoprostol from 0.95 to 0.38 percent, a relative risk reduction of 40 percent, with an absolute risk reduction of 0.57 percent (ie, 175 patients needed to be treated to reduce one complication). More patients receiving misoprostol rather than placebo withdrew from the study during the first month (20 versus 15 percent), primarily because of diarrhea and abdominal discomfort. One way to avoid or reduce misoprostol-induced diarrhea in clinical practice is to begin misoprostol at 100 &micro;g three times daily or four times daily, and then to increase the dose as tolerated up to the maximum dose of 200 &micro;g four times daily.",
"   </p>",
"   <p>",
"    Doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    lower than 200 &micro;g four times daily have been used with some success with fewer side effects. In one endoscopic trial, 1200 patients taking long-term NSAIDs were randomly assigned to one of four regimens: placebo four times daily; 200 &micro;g of misoprostol twice daily and placebo twice daily; 200 &micro;g of misoprostol three times daily and placebo once daily; and 200 &micro;g of misoprostol four times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/33\">",
"     33",
"    </a>",
"    ]. In the placebo group, the incidence of gastric ulcers detected by endoscopy was 15.7 percent. The incidence of gastric ulcers was significantly lower in the groups receiving 200 &micro;g misoprostol twice daily (8.1 percent), three times daily (3.9 percent), or four times daily (4 percent). The 7.5 percent incidence of duodenal ulcers detected by endoscopy with placebo was reduced to 2.6, 3.3, and 1.4 percent with the three respective doses of misoprostol. There were fewer withdrawals due to adverse events in the groups receiving misoprostol twice and three times daily (12 percent for both) than in the group receiving it four times daily (20 percent). Despite their possible clinical efficacy and improved patient tolerance, lower doses of misoprostol have not received FDA approval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs are useful for the prevention of NSAID-induced ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/12,34-38\">",
"     12,34-38",
"    </a>",
"    ]. An endoscopic study found that PPI use was protective (odds ratio 0.35), and none of the patients on PPIs had ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/12\">",
"     12",
"    </a>",
"    ]. In another illustrative study, the combined incidence of gastric and duodenal ulcers detected endoscopically was reduced in patients who were also treated with 20 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    per day (3.6 versus 16.5 percent with placebo at six months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/37\">",
"     37",
"    </a>",
"    ]. Clinical studies of PPIs have suggested that they are better tolerated but have slightly lower efficacy compared to full-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (ie, 200 micrograms four times daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lansoprazole versus misoprostol",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      was compared in a multicenter trial in which 537 patients who were long-term NSAID users were randomly assigned to placebo, misoprostol (200 &micro;g four times daily), or one of two doses of lansoprazole (15 or 30 mg daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/34\">",
"       34",
"      </a>",
"      ]. After 12 weeks, the incidence of endoscopically detected gastroduodenal ulceration was 49 percent with placebo and was significantly reduced with misoprostol (7 percent) and, to a lesser extent, with both doses of lansoprazole (20 and 18 percent, respectively).",
"      <br/>",
"      <br/>",
"      However, early withdrawals were more common in the misoprostol group. If withdrawals were included with endoscopic ulcers as failures of treatment, misoprostol and lansoprazole were similarly successful (31 percent failures versus 65 percent failures for those receiving placebo). Lansoprazole is approved by the US Food and Drug Administration for use in prevention of NSAID-induced gastric or duodenal ulcers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Esomeprazole with conventional NSAIDs or COX-2 inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     Esomeprazole",
"    </a>",
"    was approved for prevention of NSAID-associated ulcers based upon the results of two multicenter trials involving a total of 1429 patients who were taking NSAIDs continuously (both nonselective or COX-2 selective, with or without low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ).",
"    <br/>",
"    <br/>",
"    Patients in the studies were at increased risk for peptic ulcer disease (PUD) (either because they were older than 60 or had a history of an ulcer) and were randomly assigned to co-therapy with a PPI (20 or 40 mg of esomeprazole) or placebo for six months. All patients were",
"    <em>",
"     H. pylori",
"    </em>",
"    negative and had no active ulcer disease at randomization. The primary end point was endoscopically-detected ulcer development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/40\">",
"     40",
"    </a>",
"    ]. The major findings in a report of both studies were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcers developed in a similar proportion of patients taking a nonselective NSAID or selective COX-2 inhibitors without PPI co-therapy (17.1 versus 16.5 percent). This observation underscores that selective COX-2 inhibitors may not be protective against ulcer development in these high-risk patients.",
"     </li>",
"     <li>",
"      The cumulative proportion of patients developing ulcers at six months was significantly reduced with PPI co-therapy (17 percent with placebo versus 5.2 and 4.6 percent with the 20 and 40 mg dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      , respectively).",
"     </li>",
"     <li>",
"      The proportion of patients developing ulcers who were taking a selective COX-2 inhibitor plus a PPI was not significantly different from the proportion taking a nonselective NSAID plus a PPI (3 versus 6 percent). Thus, this study did not prove a benefit of combination treatment with a selective COX-2 inhibitor plus a PPI compared with a non-selective NSAID plus a PPI, although it may have been underpowered to detect a difference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several important limitations should be considered, in addition to the possibility of the studies being underpowered. First, only 17 percent of patients had a history of PUD and none had active ulcer disease at randomization and thus the studies focused mainly on primary prophylaxis in elderly patients. Second, patients were not randomized to a nonselective NSAID versus a selective COX-2 inhibitor. Thus, patients who were considered to be at higher risk for PUD may have been treated with a selective COX-2 inhibitor, possibly accounting for the high-rate of PUD in this group. Third, the studies focused on endoscopic, not clinical, ulcer disease. Fourth, the studies analyzed patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    as receiving a non-selective NSAID even if they were taking a selective COX-2 inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Celecoxib with low dose aspirin",
"    </span>",
"   </p>",
"   <p>",
"    A randomized endoscopic trial in low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    users compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    200 mg per day with the combination of a nonselective NSAID (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    500 mg twice daily) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/41\">",
"     41",
"    </a>",
"    ]. There was no difference between these two approaches in gastroduodenal ulcer formation, with ulcers seen in 10 and 9 percent of patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Etoricoxib versus a nonselective NSAID",
"    </span>",
"   </p>",
"   <p>",
"    Another randomized controlled trial assessed the cardiovascular toxicity of the COX-2 inhibitor etoricoxib versus the nonselective NSAID",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/42\">",
"     42",
"    </a>",
"    ]. In a prespecified analysis, etoricoxib was associated with significantly less gastrointestinal toxicity regardless of PPI or ASA co-administration. This benefit held true only for uncomplicated GI events; there was no difference between the two groups for complicated GI events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Conventional NSAID with a PPI or misoprostol versus a COX-2 inhibitor",
"    </span>",
"   </p>",
"   <p>",
"    Data are conflicting about whether COX-2 inhibitors provide additional protection compared with conventional NSAIDs combined with either a proton pump inhibitor or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 4484 patients with osteoarthritis or rheumatoid arthritis, 2238 patients were assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      and 2246 patients were assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients in the celecoxib arm were significantly less likely to develop GI toxicity compared with patients in the",
"      <span class=\"nowrap\">",
"       diclofenac/omeprazole",
"      </span>",
"      arm (1 versus 4 percent, hazard ratio 4.3).",
"     </li>",
"     <li>",
"      A population based study compared 1382 patients with upper gastrointestinal complications who were taking a conventional NSAID or a COX-2 inhibitor with 22,957 age- and sex-matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/44\">",
"       44",
"      </a>",
"      ]. Co-therapy with a PPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      or use of a COX-2 inhibitor all significantly reduced the risk of upper gastrointestinal complications. COX-2 inhibitors were not more likely to prevent complications compared with PPIs, but were superior to low dose misoprostol. The combination of a COX-2 inhibitor with a PPI was associated with the greatest degree of reduction in risk (adjusted OR 0.36 (95% CI 0.28-0.47) versus an OR of 0.67 (95% CI 0.48-0.95) for a PPI plus a conventional NSAID).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the issue of using a selective COX-2 inhibitor plus a PPI compared to a nonselective NSAID plus a PPI in patients at increased risk for PUD remains unsettled. A potential further concern with using a selective COX-2 inhibitor compared to a nonselective NSAID is their cardiovascular risks. In addition, they are much more expensive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     H2 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard doses of H2 receptor antagonists were not effective for the prevention of NSAID-induced gastric ulcers in most reports, although they may prevent duodenal ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/32\">",
"     32",
"    </a>",
"    ]. Studies that detected a benefit on gastric ulcer prevention were short-term (12 to 24 weeks) and focused on endoscopic rather than clinical endpoints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-dose H2 receptor antagonists have also been studied. Again, the trials were short-term and focused on endoscopic endpoints. In two randomized trials (REDUCE-1 and REDUCE-2), patients who required daily NSAIDs for at least six months were assigned to receive either HZT-501 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    800 mg plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    26.6 mg) or ibuprofen 800 mg three times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/47\">",
"     47",
"    </a>",
"    ]. The outcome of interest was ulcer development over 24 weeks of treatment. The pooled analysis of the two studies (a prespecified analysis in the studies&rsquo; designs) comparing HZT-501 with ibuprofen found that HZT-501 significantly reduced overall upper gastrointestinal ulcer development (14 versus 24 percent), gastric ulcer development (13 versus 21 percent), and duodenal ulcer development (2 versus 7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     COX-inhibiting nitric oxide donator NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide mediates many processes that contribute to gastric mucosal integrity, exerting similar physiological protective actions as prostaglandins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, donation of nitric oxide within the gastrointestinal tract may protect the gastric mucosa from the consequences of COX inhibition. This hypothesis provided the rationale for the development of NSAIDs that have the ability to donate nitric oxide.",
"   </p>",
"   <p>",
"    The efficacy and safety of one such drug (AZD3582) was evaluated in a controlled trial involving 970 patients with osteoarthritis who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg twice daily), the study drug (750 mg twice daily), or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/49\">",
"     49",
"    </a>",
"    ]. The primary end point was the six-week incidence of endoscopic gastroduodenal ulcers. The incidence of ulcers was lower in the study drug compared with naproxen (10 versus 14 percent) but the results did not achieve statistical significance. Despite these negative results, more studies on this class of NSAIDs are expected, particularly since they may not raise blood pressure as much as the NSAID alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18842643\">",
"    <span class=\"h2\">",
"     Aspirin-phosphatidylcholine combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study in healthy volunteers between the ages of 50 and 74 found that combining 325 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    per day with phosphatidylcholine reduced a combined endoscopic endpoint (petechiae, erosions, ulcers) compared with aspirin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/51\">",
"     51",
"    </a>",
"    ]. Long-term studies involving patients with cardiovascular disease or cardiovascular risk factors are awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CONSENSUS STATEMENTS AND GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 consensus statement regarding prevention strategies in patients taking antiplatelet agents has been issued jointly by the American College of Cardiology Foundation, The American Heart Association, and the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/52\">",
"     52",
"    </a>",
"    ]. The recommendations suggest that risk factors for gastrointestinal (GI) complications be assessed in patients requiring antiplatelet therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with a history of ulcer complications or a history of ulcer disease (non-bleeding) undergo testing for",
"      <em>",
"       H. pylori",
"      </em>",
"      and treatment if positive.",
"     </li>",
"     <li>",
"      Those with a history of ulcer complications or a history of ulcer disease (non-bleeding), a history of upper gastrointestinal bleeding, those receiving dual antiplatelet therapy or concomitant anticoagulants be treated with a proton pump inhibitor (PPI).",
"     </li>",
"     <li>",
"      Patients without the above risk factors but who have other risk factors for gastrointestinal complications (including age 60 or more, use of corticosteroids, dyspepsia or gastroesophageal reflux disease symptoms) should also be treated with a PPI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American College of Gastroenterology independently published additional guidelines in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38393/abstract/7\">",
"     7",
"    </a>",
"    ]. These guidelines risk stratify patients into high, moderate, or low risk for GI complications of nonsteroidal antiinflammatory drug (NSAID) use based upon the number of positive risk factors they have. High risk patients were defined as having a history of a previous complicated ulcer (especially recent) or &gt;2 other risk factors (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk factors'",
"    </a>",
"    above). Low risk patients have no risk factors while moderate risk patients have one to two risk factors.",
"   </p>",
"   <p>",
"    The guidelines also addressed cardiovascular (CV) risk. High risk CV patients were arbitrarily defined as those who required low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    These guidelines advise five different strategies depending upon a patient's combined GI and CV risk profile:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are at high",
"      <span class=\"nowrap\">",
"       GI/high",
"      </span>",
"      CV risk should not receive NSAIDs, including COX-2 inhibitors.",
"     </li>",
"     <li>",
"      Patients at high",
"      <span class=\"nowrap\">",
"       GI/low",
"      </span>",
"      CV risk should receive a COX-2 inhibitor in combination with either a PPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients at moderate",
"      <span class=\"nowrap\">",
"       GI/low",
"      </span>",
"      CV risk should receive a COX-2 inhibitor alone or a conventional NSAID + either a PPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients at moderate",
"      <span class=\"nowrap\">",
"       GI/high",
"      </span>",
"      CV risk should receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (due to its putative cardioprotective properties) and either a PPI or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      . This same strategy is endorsed for patients at low",
"      <span class=\"nowrap\">",
"       GI/high",
"      </span>",
"      CV risk.",
"     </li>",
"     <li>",
"      Patients at low",
"      <span class=\"nowrap\">",
"       GI/low",
"      </span>",
"      CV risk can receive a conventional NSAID alone, although the \"least ulcerogenic NSAID at the lowest effective dose\" is recommended (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonselective NSAIDs'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      All patients regardless of risk who are about to start long-term traditional NSAID therapy should be considered for testing for",
"      <em>",
"       H. pylori",
"      </em>",
"      and treated if positive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9853419\">",
"    <span class=\"h1\">",
"     MONITORING PATIENTS TAKING NSAIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring patients while on NSAIDs can be difficult since many patients who develop GI toxicity are asymptomatic until shortly before the adverse event occurs. An NSAID-induced gastrointestinal complication should be suspected if the patient develops unexplained blood loss anemia, iron deficiency, severe dyspepsia, or exhibits overt GI bleeding. The appropriate test to order is upper gastrointestinal endoscopy, unless ulcer perforation is suspected in which case computed tomography (CT) scan of the abdomen or, if unavailable immediately, an upright chest X-ray and plain abdominal films should be ordered immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, multiple studies have evaluated a variety of strategies for preventing ulcers in patients requiring nonsteroidal antiinflammatory drugs (NSAIDs). The following represents recommendations based upon the available data and expert consensus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of gastroduodenal toxicity is related to risk factors described above, the patient's",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      (",
"      <em>",
"       H. pylori",
"      </em>",
"      ) status, and the specific type and dose of NSAID. Significant gastrointestinal (GI) toxicity generally does not begin for several weeks, although it can appear as early as seven days with some NSAIDs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability to modify the risk depends upon the clinical setting. As noted above, patients with a history of uncomplicated or complicated peptic ulcers (gastric, duodenal) should be tested for",
"      <em>",
"       H. pylori",
"      </em>",
"      prior to beginning a NSAID or low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . If present,",
"      <em>",
"       H. pylori",
"      </em>",
"      should be treated with appropriate therapy, even if it is believed that the prior ulcer was due to NSAIDs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Role of Helicobacter pylori'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attempts should be made to use the lowest dose and shortest duration of NSAID treatment that is feasible. While it is preferable to use NSAIDs with the lowest potential for GI toxicity, all NSAIDs are associated with an increased risk.",
"     </li>",
"     <li>",
"      In asymptomatic patients with no history of ulcer and not currently taking an NSAID, physicians can consider",
"      <em>",
"       H. pylori",
"      </em>",
"      testing prior to beginning long-term therapy with a NSAID. It is possible that successfully treating",
"      <em>",
"       H. pylori",
"      </em>",
"      infection in such individuals will reduce the risk of NSAID-related ulcer complications, but additional studies of this approach are needed. This \"test-and-treat\" approach may be more useful in populations with a relatively high prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      infection. On the other hand, we recommend testing for",
"      <em>",
"       H. pylori",
"      </em>",
"      in patients with a history of peptic ulcer disease or complications (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=see_link\">",
"       \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have multiple risk factors for NSAID-related gastroduodenal toxicity, options include therapy with a COX-2 selective inhibitor or a nonselective NSAID in combination with a proton pump inhibitor (PPI) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      . High-dose H2 receptor antagonists are a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Selective COX-2 inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend coadministration of a PPI in patients who require an NSAID and are at high or moderate risk for GI toxicity (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.) We prefer PPIs to other preventive approaches because of their convenience and relatively good safety profile.",
"     </li>",
"     <li>",
"      We agree with the 2009 ACG guidelines that NSAID therapy is best avoided in patients at high risk from both GI and cardiovascular (CV) standpoints. However, we feel that CV risk should be assessed on a case by case basis rather than being defined by the use of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . We do not believe the balance of evidence as yet supports preferential use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      over other nonselective NSAIDs in patients at moderate or low GI risk and high CV risk. We also believe that the use of a COX-2 inhibitor plus a PPI in high risk groups should be considered on a case by case basis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Consensus statements and guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approved doses of these drugs in patients taking nonselective NSAIDs include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (200 &micro;g four times daily),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      (15 or 30 mg daily), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      (20 or 40 mg daily). Although not all PPIs have received FDA approval, they probably all have similar effectiveness.",
"     </li>",
"     <li>",
"      Concerns related to cardiovascular risks of the COX-2 inhibitors make it likely that they will have a diminishing clinical role, while use of relatively safer NSAIDs plus a PPI will have an increasing role. A PPI is generally preferred to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      since PPIs are generally better tolerated and more convenient. Misoprostol usually requires therapy four times daily at the approved dose for gastrointestinal prophylaxis (200 micrograms four times daily). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiovascular risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a COX-2 inhibitor is used, it is important to realize that any GI protective effect that may result is eliminated with the concomitant use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for cardiovascular prophylaxis. Thus, there is no advantage of using a coxib in this subgroup of patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Celecoxib with low dose aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An NSAID-induced gastrointestinal complication should be suspected if the patient develops unexplained blood loss anemia, iron deficiency, severe dyspepsia, or exhibits overt GI bleeding. Patients who develop NSAID-induced non-ulcer dyspepsia may respond to H2 antagonists or proton pump inhibitors at standard doses, but of these choices only PPIs also reduce the risk of NSAID-induced ulcer or its complications. Development of dyspepsia may signal that an ulcer has developed at which point an upper endoscopy can be considered. Switching to a different NSAID or to a COX-2 inhibitor may eliminate dyspepsia and obviate the need for an H2 antagonist or proton pump inhibitor.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       Misoprostol",
"      </a>",
"      does not reduce, and may even increase, dyspeptic symptoms. (See",
"      <a class=\"local\" href=\"#H9853419\">",
"       'Monitoring patients taking NSAIDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Misoprostol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/1\">",
"      Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/2\">",
"      Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/3\">",
"      Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/4\">",
"      Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996; 28:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/5\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/6\">",
"      Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010; 32:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/7\">",
"      Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/8\">",
"      Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/9\">",
"      Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/10\">",
"      Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/11\">",
"      Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/12\">",
"      Tamura A, Murakami K, Kadota J, OITA-GF Study Investigators. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM 2011; 104:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/13\">",
"      Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004; 63:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/14\">",
"      Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology 2004; 127:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/15\">",
"      Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA 1996; 275:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/16\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/17\">",
"      Reinhart DI. Minimising the adverse effects of ketorolac. Drug Saf 2000; 22:487.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019645s017lbl.pdf (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/19\">",
"      Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/20\">",
"      Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993; 15:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/21\">",
"      Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/22\">",
"      Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/23\">",
"      van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008; 6:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/24\">",
"      Kiltz U, Zochling J, Schmidt WE, Braun J. Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology (Oxford) 2008; 47:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/25\">",
"      Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/26\">",
"      Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/27\">",
"      Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/28\">",
"      Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/29\">",
"      Mamdani M, Juurlink DN, Kopp A, et al. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004; 328:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/30\">",
"      Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/31\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/32\">",
"      Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/33\">",
"      Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/34\">",
"      Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/35\">",
"      Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/36\">",
"      Ekstr&ouml;m P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/37\">",
"      Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/38\">",
"      Lin KJ, Hern&aacute;ndez-D&iacute;az S, Garc&iacute;a Rodr&iacute;guez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011; 141:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/39\">",
"      Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/40\">",
"      Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/41\">",
"      Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/42\">",
"      Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/43\">",
"      Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/44\">",
"      Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008; 134:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/45\">",
"      Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/46\">",
"      Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/47\">",
"      Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012; 107:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/48\">",
"      Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/49\">",
"      Lohmander LS, McKeith D, Svensson O, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005; 64:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/50\">",
"      Fiorucci S, Santucci L, Distrutti E. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liver Dis 2007; 39:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/51\">",
"      Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011; 106:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38393/abstract/52\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008; 103:2890.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 35 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38393=[""].join("\n");
var outline_f37_31_38393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NONSELECTIVE NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENTERIC-COATED AND BUFFERED ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Low dose aspirin for cardiovascular protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dual antiplatelet therapy (eg, aspirin and clopidogrel)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROLE OF HELICOBACTER PYLORI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SELECTIVE COX-2 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lansoprazole versus misoprostol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Esomeprazole with conventional NSAIDs or COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Celecoxib with low dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Etoricoxib versus a nonselective NSAID",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Conventional NSAID with a PPI or misoprostol versus a COX-2 inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      H2 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COX-inhibiting nitric oxide donator NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18842643\">",
"      Aspirin-phosphatidylcholine combination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CONSENSUS STATEMENTS AND GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9853419\">",
"      MONITORING PATIENTS TAKING NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/35\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/35|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/4/25675\" title=\"table 1\">",
"      Patients at increased risk for NSAID gastrointestinal toxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10375?source=related_link\">",
"      COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26947?source=related_link\">",
"      NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38394="Immunosuppression in renal transplantation in children";
var content_f37_31_38394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunosuppression in renal transplantation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38394/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38394/contributors\">",
"     Ruth A McDonald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38394/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/31/38394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/31/38394/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/31/38394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H35218094\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major advance allowing prolonged allograft survival in pediatric renal transplantation has been the use of immunosuppressive drugs that down-regulate the immune response. The goal remains to find the best combination of immunosuppressive agents that optimizes allograft survival by preventing acute rejection while limiting drug toxicities. Although data from adult renal transplantation trials are used to help guide management decisions in pediatric patients, immunosuppression often must be modified because of the unique clinical effects of some of these agents in children including their impact on growth and development.",
"   </p>",
"   <p>",
"    An overview of immunosuppression regimens used in children undergoing renal transplantation will be reviewed here. Additional issues concerning transplantation in children as well as detailed discussions of immunosuppressive issues in renal transplantation common to both children and adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23543?source=see_link\">",
"     \"General principles of kidney transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40680?source=see_link\">",
"     \"Outcomes of renal transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2175234\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of immunosuppression is to prevent acute rejection while minimizing drug side effects. In children who undergo renal transplantation, immunosuppression is divided into the three following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy &ndash; Intensive immunosuppression administered during the perioperative period to prevent acute rejection",
"     </li>",
"     <li>",
"      Maintenance therapy &ndash; Immunosuppressive therapy to prevent acute rejection after the perioperative period",
"     </li>",
"     <li>",
"      Treatment of acute rejection &ndash; Immunosuppressive therapy to treat acute rejection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, immunosuppression should be highest during the first three months after transplantation when the risk of acute rejection and allograft loss is greatest. Immunosuppression is tapered slowly to a maintenance level by 6 to 12 months post-transplantation.",
"   </p>",
"   <p>",
"    The immunosuppression that is used varies among transplant centers and has evolved with the development of new medications. In addition, many centers now consider the following patient specific factors in choosing which immunosuppressive medications to administer to the transplant recipient. In general, more intensive immunosuppression is selected for patients who are at greater risk for allograft rejection or loss.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the patient sensitized?",
"     </li>",
"     <li>",
"      Is this the first kidney transplant or a retransplant?",
"     </li>",
"     <li>",
"      How many acute rejection episodes has the patient had?",
"     </li>",
"     <li>",
"      What is the degree of HLA matching or mismatching? (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link\">",
"       \"HLA matching and graft survival in kidney transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      What is the risk of recurrent disease?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218101\">",
"    <span class=\"h1\">",
"     INDUCTION IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy is used to prevent T-cell activation and is administered during the perioperative period when the risk of acute rejection is highest. It generally includes the use of antibodies directed against T-cell antigens in combination with conventional agents. In adults, a large number of controlled randomized trials and meta-analyses indicate that induction therapy consisting of biologic antibodies plus conventional immunosuppressive therapy (eg, corticosteroids, antimetabolites,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcineurin inhibitor) is superior to conventional agent therapy alone in reducing renal allograft rejection and failure. In children, data are limited on the optimal induction therapy that prevents allograft rejection and failure while minimizing serious adverse effects (eg, infections and malignancies). As a result, the choice of induction therapy for children in pediatric renal transplantation remains controversial and dependent upon center preference based on patient factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link&amp;anchor=H2#H2\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'Overview of our approach to induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2175257\">",
"    <span class=\"h2\">",
"     Antibody induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody induction agents include specific antilymphocyte or interleukin-2 (IL-2) receptor antibodies (ie, antagonist) that target T-cells. Data from adult trials have demonstrated that induction therapy consisting of biologic antibodies plus conventional immunosuppressive agent therapy is superior to conventional agent therapy alone in reducing kidney allograft rejection and allograft failure.",
"   </p>",
"   <p>",
"    In contrast, to date, no controlled trials in pediatric renal transplant recipients have verified the benefit of using induction antibody therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/1\">",
"     1",
"    </a>",
"    ]. In fact, a large controlled trial of OKT3 induction versus induction with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in pediatric kidney transplantation showed no additional benefit to antibody induction over the use of cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/2\">",
"     2",
"    </a>",
"    ]. However, observational data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) consistently show a beneficial effect of prophylactic anti T-cell antibody therapy in pediatric renal transplant allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/3\">",
"     3",
"    </a>",
"    ]. These results are subject to confounding variables such as center effect, and the use of several different types of T-cell antibody, and other nonbiologic agents. Based upon the results from the adult trials and the NAPRTCS registry, antibody induction therapy should be used in conjunction with conventional immunosuppression in pediatric renal transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, results from two large prospective randomized controlled trials in pediatric patients showed induction therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    (anti-interleukin-2 receptor monoclonal antibody [IL-2R antibodies]) in patients with low to medium immunological risk on maintenance therapy (consisting of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in conjunction with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in conjunction with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF)) did not lead to a statistically significant reduction in the incidence of acute rejection episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, there is presently no consensus amongst pediatric renal transplantation centers regarding the use and regimen for immunosuppressive induction therapy. Although the current choice of induction therapy is center and patient dependent, considerations in choosing the appropriate agent include the efficacy in the patient population (eg, high-risk or low-risk for graft loss recipients) and the side effect profile.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no consistent evidence that shows induction therapy is beneficial or cost-effective in low to medium risk patients who receive triple therapy with calcineurin inhibitors in conventional doses, MMF, and glucocorticoids.",
"     </li>",
"     <li>",
"      Induction therapy appears to produce the greatest benefits in groups at high-risk for allograft rejection. These high risk groups include African-Americans, recipients of kidneys with prolonged cold ischemia time, and those at high immunologic risk, particularly individuals who are presensitized. The sequential induction regimen of thymoglobulin or IL-2R blocking antibodies followed by",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is recommended in these high-risk groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A center may opt to use an IL-2 receptor antagonist for induction in the unsensitized recipient, but use antilymphocyte antibody therapy in a highly sensitized patient or a patient who has had a previous failed transplant.",
"   </p>",
"   <p>",
"    Trends in induction therapy have changed over time with a shift away from the polyclonal and monoclonal antilymphocyte antibody preparations towards the IL-2 receptor antagonists (",
"    <a class=\"graphic graphic_figure graphicRef59479 \" href=\"mobipreview.htm?26/60/27599\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ]. However, this trend may be reversed if new data continue to show a lack of additional benefit from IL-2 receptor antagonists. (See",
"    <a class=\"local\" href=\"#H35218129\">",
"     'Anti-interleukin 2 receptor antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218108\">",
"    <span class=\"h3\">",
"     Antilymphocyte antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antilymphocyte antibodies to T-cells block lymphocyte functions by the direct killing of bound T lymphocytes. These agents are used to reverse and prevent acute rejection episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both polyclonal and monoclonal preparations are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218115\">",
"    <span class=\"h4\">",
"     Polyclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal preparations consist of antisera raised in animals (eg, horse, rabbit) immunized with human lymphocytes, thymocytes, or lymphoblasts. They contain a wide variety of antibodies directed against many hematopoietic antigens, including cluster determinant (CD) 2, CD3, CD4, CD8, CD18, and human leukocyte antigen (HLA) molecules.",
"   </p>",
"   <p>",
"    The following two polyclonal lymphocyte depleting antibodies are currently available:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anti-thymocyte globulin (ATGAM) is a polyclonal horse-derived antilymphocyte globulin.",
"     </li>",
"     <li>",
"      rATG-thymoglobulin (Thymoglobulin&reg;) is a polyclonal rabbit-derived antilymphocyte globulin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a single center historic cohort study of pediatric renal transplant recipients, similar patient and allograft survival rates were seen in patients treated with either ATGAM (mean follow-up of 90 months) or rATG-thymoglobulin (mean follow-up of 32 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/8\">",
"     8",
"    </a>",
"    ]. Although there were no differences in the incidences of chronic allograft nephropathy and Epstein-Barr virus lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/8\">",
"     8",
"    </a>",
"    ], the incidence of acute rejection was noted to be lower in the group treated with rATG-thymoglobulin. This result may be due to the rATG-thymoglobulin group being a more recently treated cohort, and the outcomes of kidney transplantation have generally improved with time. However, clinical trial in adults also demonstrated lower acute rejection rates in patients who received rATG-thymoglobulin compared to those treated with ATGAM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link&amp;anchor=H6#H6\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'rATG-thymoglobulin versus ATGAM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies from single centers that used rATG-thymoglobulin induction in combination with steroid minimization, calcineurin inhibitor, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil maintenance immunosuppression reported good recipient and graft survival and comparable rejection rates to historic steroid-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It is important to note that extended follow-up and further study are needed to determine whether this combination of therapy increases the incidence of post-transplant lymphoproliferative disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link&amp;anchor=H6#H6\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'rATG-thymoglobulin versus ATGAM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218122\">",
"    <span class=\"h4\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies have been produced to different T-cell surface receptors and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OKT3 &ndash; OKT3 (Muronab-CD3, Orthoclone&reg;) was the first monoclonal antilymphocyte antibody used in clinical transplantation. It binds to the lymphocyte CD3 complex resulting in rapid cell lysis, therefore inhibiting almost all T-cell functions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/11\">",
"       11",
"      </a>",
"      ]. Currently, few pediatric transplant recipients receive OKT3 for induction therapy because there is no clear benefit of OKT3 compared with other antilymphocyte antibody preparations and it has significant adverse effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/2,6,12\">",
"       2,6,12",
"      </a>",
"      ]. This includes the &ldquo;first-dose reaction,&rdquo; which occurs in more than two-thirds of patients, and consists of fever, chills, headache, vomiting, diarrhea, hypotension, and occasionally pulmonary edema. In addition, the use of OKT3 is limited by the formation of anti-OKT3 antibodies, which commonly occurs in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       Alemtuzumab",
"      </a>",
"      (Campath-1H) &ndash; Alemtuzumab is a humanized anti-CD52 antibody. Although CD52 is the most prevalent cell surface antigen on lymphocytes, its function is currently unknown [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/14\">",
"       14",
"      </a>",
"      ]. After administration, alemtuzumab quickly depletes T and B lymphocytes, monocytes, and natural killer cells with its effects lasting for months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/15\">",
"       15",
"      </a>",
"      ]. Alemtuzumab is approved for treatment of chronic lymphocytic leukemia but it is not currently approved for organ transplantation. Patients who undergo renal transplantation must be informed of its off-label use and its evolving experimental nature. The dose and frequency of administration of alemtuzumab, and the optimal maintenance immunosuppressive regimen to be utilized with this agent remain to be determined.",
"      <br/>",
"      <br/>",
"      Alemtuzumab is currently undergoing clinical trials as a lymphocyte depleting agent in both pediatric and adult renal transplantation with a goal of eliminating or minimizing the use of corticosteroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcineurin inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/14\">",
"       14",
"      </a>",
"      ]. In an observational study, induction therapy with alemtuzumab followed by eventual monotherapy with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      has been successfully used in avoiding the administration of corticosteroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is no currently recommended dose for children, but 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose has been the most commonly used dose of alemtuzumab in pediatric studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/18\">",
"       18",
"      </a>",
"      ]. The most common number of doses administered was two doses with a range from one to four doses during the first week post-transplantation.",
"      <br/>",
"      <br/>",
"      Due to infusion-related reactions, premedication with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      is recommended and the administration of antiemetics as needed for nausea and vomiting. The major side effect that limits the use of alemtuzumab is profound lymphopenia, which may contribute to significant adverse events including infections, autoimmune complications, and malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/18\">",
"       18",
"      </a>",
"      ]. In one small series of high-risk pediatric kidney transplant recipients, although alemtuzumab was well tolerated, acute rejection occurred in three of the four patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/14\">",
"       14",
"      </a>",
"      ]. The Cooperative Clinical Trials in Pediatric Transplantation (CCTPT) program of the National Institute of Allergy and Infectious Disease (NIAID) has completed a multicenter pilot trial of alemtuzumab induction in pediatric renal transplant recipients with initial maintenance immunosuppression of tacrolimus and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF), but the results have yet to be published.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218129\">",
"    <span class=\"h3\">",
"     Anti-interleukin 2 receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full T-cell activation leads to the calcineurin-mediated stimulation of the transcription, translation, and secretion of interleukin-2 (IL-2), which induces T-cell proliferation. Thus, abrogation of IL-2 activity via the administration of anti-IL-2 receptor antibodies would be an attractive potential therapeutic option for the prevention of acute rejection.",
"   </p>",
"   <p>",
"    The only IL-2 receptor antibody that is currently available is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    (Simulect&reg;), a chimeric",
"    <span class=\"nowrap\">",
"     human/mouse",
"    </span>",
"    monoclonal antibody to the alpha chain of the IL-2 receptor. In October 2008, Roche pharmaceuticals voluntarily withdrew the marketing authorization for daclizumab (ZenapaxTM), a humanized interleukin-2 receptor antibody, because of reduced market demands.",
"   </p>",
"   <p>",
"    Data from two large, randomized clinical trials suggest that the addition of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    to conventional non-antibody induction therapy (eg, standard-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , corticosteroids, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/5\">",
"     5",
"    </a>",
"    ] or standard-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , corticosteroids, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]) does not improve clinical outcome in children who undergo renal transplantation. In addition, clinical trials in adult renal transplant recipients demonstrated that other antibody agents (eg, rATG-thymoglobulin) were associated with lower rates of acute rejection, combined outcomes of allograft loss and death, all causes of mortality, and delayed allograft function than basiliximab. There were, however, significantly fewer adverse events observed with IL-2 antagonists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link&amp;anchor=H10#H10\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'IL-2 receptor antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, a large, randomized controlled study showed that two doses of daclizumab in pediatric renal transplant recipients on standard dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and MMF allowed early steroid withdrawal on day five post-transplant with a comparable rate of biopsy proven acute rejection rates after six months in patients off steroid (10.2 percent) compared to controls (7.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing studies in the United States and Europe are currently investigating the potential of IL-2R antibodies as a replacement for corticosteroids therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on the positive outcome in an uncontrolled pilot trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/21\">",
"     21",
"    </a>",
"    ], a Cooperative Clinical Trials in Pediatric Transplantation (CCTPT) prospective randomized multicenter trial of steroid-free immunosuppression using extended daclizumab,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and MMF versus steroid-based therapy in conjunction with standard daclizumab, tacrolimus, and MMF was performed. Although a three year follow-up has been completed, the results have not yet been published. Our center participated in this trial, and after the trial closed, we continue to use the extended daclizumab steroid-free arm as our standard approach for immunosuppression in low risk candidates until daclizumab was no longer manufactured.",
"   </p>",
"   <p>",
"    Based on published data from both pediatric and adult trials, our current practice is to use an antilymphocyte antibody such as rATG-thymoglobulin rather than an IL-2 antagonist in steroid minimization regimens and in high risk patients, unless further studies indicate a clear increased benefit of IL-2 antagonists over alternate antibody induction agents this group of patients.",
"   </p>",
"   <p>",
"    Other centers use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    in combination with corticosteroids resulting in good outcome because of the lower rate of adverse effects and possible decrease risk of complications associated with antilymphocyte antibodies (rATG-thymoglobulin, ATGAM and OKT3) including post-transplant lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    is used, a dosing schedule has been suggested based on an analysis of a pharmacokinetic study of basiliximab in 39 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. The regimen consists of the administration of two 10 mg doses to children &lt;35 kg in weight and two 20 mg doses to children &ge; 35 kg in weight, with the first dose given with surgery and the second on post-transplant day four. In the 14 patients who were evaluated, the mean duration of IL-2 receptor saturation was 42 &plusmn; 16 day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a larger study of 82 patients who received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), MMF reduced basiliximab clearance and prolonged CD25 saturation from 5 to 10 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86243149\">",
"    <span class=\"h2\">",
"     Nonbiological agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonbiological agents that have been used as induction therapy include corticosteroids, calcineurin inhibitors (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and less frequently",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ), and antimetabolites (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , and less frequently",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ]. These agents, when given as induction therapy, are administered at higher doses than when used as maintenance therapy. Currently, most nonbiological agents are generally started at maintenance doses in combination with antibody induction therapy at the time of transplantation.",
"   </p>",
"   <p>",
"    Corticosteroids are the most frequently used nonbiological agents for induction therapy in children undergoing renal transplantation. When used as part of an induction regimen, the initial dose(s) used is high (eg, up to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    for one or two doses) and then lowered to a maintenance dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    starting at 2",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H35222050\">",
"     'Corticosteroids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218143\">",
"    <span class=\"h1\">",
"     MAINTENANCE IMMUNOSUPPRESSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694166221\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance immunosuppressive therapy is administered to prevent acute rejection and the loss of the renal allograft. With the development of new agents, the focus of the transplant community is to establish regimens that maintain excellent allograft survival rates but with fewer toxicities (eg, infection, nephrotoxicity, malignancy, cosmetic effects, and growth impairment). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40680?source=see_link&amp;anchor=H3#H3\">",
"     \"Outcomes of renal transplantation in children\", section on 'Effect of immunosuppressive regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the need to continue to use these medications on a continuing daily basis requires adherence. A systematic review of the literature reported nonadherence rate of 32 percent in pediatric renal transplant recipients below 21 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/29\">",
"     29",
"    </a>",
"    ]. The rate is higher in adolescents, perhaps due to the adverse cosmetic effects of some of the immunosuppressive agents (eg, corticosteroids and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Maintenance immunosuppression regimens generally consist of a combination of agents with different mechanisms of action. As a result, patients are at-risk for drug interactions that may modify the effects of the various medications. Drug therapy should be managed by transplant specialist with expertise in therapeutic drug monitoring and dosing, and potential drug interactions (",
"    <a class=\"graphic graphic_table graphicRef81998 \" href=\"mobipreview.htm?14/44/15042\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following sections include descriptions of these individual agents used in pediatric renal transplantation and a discussion of immunosuppressive combinations used in maintenance immunosuppression. (See",
"    <a class=\"local\" href=\"#H35218229\">",
"     'Immunosuppression combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35222050\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive effect of corticosteroids is primarily based on their ability to inhibit the activation and proliferation of T-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/31\">",
"     31",
"    </a>",
"    ]. These agents inhibit the transcription of genes that code for several cytokines, such as IL-1, IL-2, IL-6, interferon-gamma, and tumor necrosis factor-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Corticosteroids also dampen the activity of monocytes and neutrophils, but have little effect upon the antibody response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial corticosteroid therapy is usually administered during surgery and the first one or two days postoperatively as intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    . Doses vary from 2 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight, with the higher dosing used as induction therapy. (See",
"    <a class=\"local\" href=\"#H86243149\">",
"     'Nonbiological agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Within one or two days post-transplant, maintenance therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    is commonly started at 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (60",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day), with a gradual reduction to approximately 0.12 to 0.16",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day within a 6 to 12 month period. Alternate-day dosing is often administered 6 to 12 months post-transplant to minimize the effect of corticosteroids on growth.",
"   </p>",
"   <p>",
"    Some drugs (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ) can accelerate the catabolism of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . As a result, these agents should be used with caution whenever corticosteroid therapy is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218157\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids have multiple side effects in children, including growth impairment, susceptibility to infections, cushingoid appearance, acne, hypertension, aseptic bone necrosis, cataracts, hyperglycemia, poor wound healing, and psychological effects. The negative impact that corticosteroids have on appearance may play a role in poor adherence, especially in the body image conscious adolescent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most important reasons for withdrawal of corticosteroids or switching to alternate day therapy is statural growth impairment, which is frequently observed in those on continuous daily treatment. The use of alternate-day steroid therapy, which appears to reduce the growth-inhibiting effect without unduly increasing rejection episodes, is the most common approach to minimize corticosteroids side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of short stature\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533861718\">",
"    <span class=\"h3\">",
"     Corticosteroid withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the multiple adverse effects of maintenance corticosteroid therapy, attempts have been made to withdraw or minimize corticosteroid therapy in children with a renal allograft. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter CCTPT study that used an immunosuppressive regimen of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"       basiliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      , calcineurin inhibitor, and corticosteroids, 274 patients were randomly assigned to either steroid withdrawal or continued low-dose steroids at six months after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/37\">",
"       37",
"      </a>",
"      ]. Although there were no differences in the rates of acute rejection episodes or three-year allograft survival, the unacceptable rate of post-transplant lymphoproliferative disorders associated with this immunosuppressive regimen resulted in stopping the study before complete enrollment was achieved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a smaller trial of 42 patients with low-immunologic risk who were maintained on",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and corticosteroids, patients were randomly assigned at one year after renal transplantation to either corticosteroid continuation or withdrawal over a three-month period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/40\">",
"       40",
"      </a>",
"      ]. At one year follow-up, the corticosteroid-withdrawal group had increased catch-up growth, lower arterial blood pressure, and a better carbohydrate and lipid profile than those who continued on corticosteroid therapy.",
"      <br/>",
"      <br/>",
"      In a subsequent follow-up report, the prevalence of the metabolic syndrome declined in the withdrawal group from 39 percent at baseline to 6 percent two years after discontinuing steroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/42\">",
"       42",
"      </a>",
"      ]. Allograft function remained stable in the withdrawal group compared to controls, and the incidence of acute rejections was similar in the steroid-withdrawal and the control groups (4 versus 11 percent).",
"     </li>",
"     <li>",
"      In a randomized controlled study in 196 pediatric renal transplant recipients, two doses of daclizumab in patients treated with a regimen of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and MMF allowed early steroid withdrawal on day five post-transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/20\">",
"       20",
"      </a>",
"      ]. There was a comparable rate of biopsy proven acute rejection rates after six months in patients off steroids compared to controls (10.2 versus 7.1 percent). In addition, prepubertal patients with early steroid withdrawal compared with controls had better growth, and lipid and glucose metabolism profiles without increases in graft rejection or loss. &nbsp;",
"     </li>",
"     <li>",
"      An uncontrolled pilot trial of prolonged daclizumab (IL-2 receptor antibody) administration and steroid avoidance showed promising results with low acute rejection rates and low incidence of complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/21\">",
"       21",
"      </a>",
"      ]. However, daclizumab is no longer available. (See",
"      <a class=\"local\" href=\"#H35218129\">",
"       'Anti-interleukin 2 receptor antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A retrospective review of 129 patients from a single center reported a 13 percent failure rate of conversion to a corticosteroid-free immunosuppression regimen, primarily due to acute rejection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/38\">",
"       38",
"      </a>",
"      ]. Patient survival was similar in patients who remained corticosteroid-free and those who required a return to corticosteroid therapy, but allograft survival was poorer in those who continued to require corticosteroid therapy.",
"     </li>",
"     <li>",
"      In a case series of 19 consecutive primary kidney transplant recipients who were treated with an immunosuppressive regimen of rATG-thymoglobulin,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and five daily doses of corticosteroids, 17 patients were successfully weaned from corticosteroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/39\">",
"       39",
"      </a>",
"      ]. The other two patients had recurrence of their primary disease (focal segmental glomerulosclerosis), and corticosteroid therapy was restarted. All patients weaned from corticosteroids had good allograft function at a mean followup of 27 months post-transplantation.",
"     </li>",
"     <li>",
"      In another case series of 20 consecutive primary kidney transplant recipients, outcome at one year post-transplantation was similar in patients treated with an induction regimen of rATG-thymoglobulin and a maintenance regimen of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      compared with historical controls who received an induction regimen of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"       basiliximab",
"      </a>",
"      and high-dose",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      followed by a maintenance regimen of mycophenolate mofetil, tacrolimus, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/43\">",
"       43",
"      </a>",
"      ]. Although the benefits of using steroid free protocols in pediatric patients shows great promise, further study is needed to determine the impact on long-term allograft function and to identify patients (eg, low-immunologic risk) who can be successfully converted to corticosteroid-free immunosuppression without increasing the risk of acute rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176355543\">",
"    <span class=\"h4\">",
"     Recurrent renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because recurrent disease is the fourth most common cause of graft loss in children undergoing renal transplantation, there have been concerns that corticosteroid withdrawal may be associated with an increase risk of graft loss. Although information is limited, a study demonstrated no difference in graft survival in children (4 to 18 years of age) treated with a rapid",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    discontinuation protocol compared with historical controls who received corticosteroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/44\">",
"     44",
"    </a>",
"    ]. However, more data are needed to ensure there is not an untoward increased risk of recurrent disease with corticosteroid withdrawal. In particular, the effect of corticosteroid withdrawal on recurrence may vary depending on the primary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218164\">",
"    <span class=\"h2\">",
"     Antimetabolic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218173\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is converted in the liver to 6-mercaptopurine, the active metabolite, which is incorporated into DNA. This impairs adenine and guanine synthesis, inhibits DNA and RNA synthesis, and blocks gene replication and cell division [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/45\">",
"     45",
"    </a>",
"    ]. Since azathioprine is primarily an antiproliferative agent, this drug does not affect the number of peripheral blood lymphocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link&amp;anchor=H6#H6\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Azathioprine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    is given at doses of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day when used in conjunction with corticosteroids alone.",
"    <strong>",
"    </strong>",
"    With a triple therapy regimen, the dose is lower, ranging from 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day. In 1989 and 1990, 80 percent of pediatric patients in the NAPRTCS registry were receiving azathioprine, but with increased familiarity with the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, the administration of azathioprine has diminished substantially and is currently used in less than 5 percent of pediatric kidney transplant patients in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218180\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effect of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    is myelosuppression with leukopenia, thrombocytopenia, and megaloblastic anemia. Other side effects include susceptibility to viral infection, hepatotoxicity, pancreatitis, alopecia, and neoplasia, most notably skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/46\">",
"     46",
"    </a>",
"    ]. Azathioprine has been used in combination with all other immunosuppressant agents except",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, which has a similar mechanism of action (ie, inhibiting purine synthesis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link&amp;anchor=H6#H6\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Azathioprine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218187\">",
"    <span class=\"h3\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF), the prodrug of the active immunosuppressant mycophenolic acid, is an inhibitor of inosine 5-phosphate dehydrogenase and guanosine monophosphate synthetase. MMF reduces de novo purine synthesis in T and B lymphocytes, thereby inhibiting lymphocyte proliferation and antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/47\">",
"     47",
"    </a>",
"    ]. MMF was developed as a replacement for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    for maintenance immunosuppression and as rescue therapy in patients with rejection episodes refractory to OKT3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. It has less bone marrow toxicity than azathioprine.",
"   </p>",
"   <p>",
"    Data from the NAPRTCS registry showed that MMF was administered to 67 percent of pediatric renal transplant recipients in the United States in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ]. MMF is currently available in intravenous, capsule, and liquid form.",
"   </p>",
"   <p>",
"    The use of MMF appears to be safe and beneficial among children as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a German open-label study of children (18 years of age and younger) who received MMF in combination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (CSA) and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , five-year allograft survival rate evaluated in 64 of the original 140 enrolled patients was higher in patients who received MMF compared to historical controls treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      (91 versus 67 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Dutch study, 96 consecutive patients treated with MMF in combination with CSA and corticosteroids had better one-year allograft survival than historic controls treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      , CSA, and a variety of different combinations of corticosteroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/52\">",
"       52",
"      </a>",
"      ]. There was a lower rate of acute rejection in the MMF group (37 versus 72 percent).",
"     </li>",
"     <li>",
"      In an international, multicenter study of 100 patients treated with MMF, CSA, and corticosteroids, the three-year patient and allograft survival rates were 98 and 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/53\">",
"       53",
"      </a>",
"      ]. About three-quarters of the patients also received anti-lymphocyte antibody induction therapy. Three years after transplantation, the acute rejection rate (biopsy-proven rejections or presumed rejection requiring anti-rejection therapy) was 26 percent with induction therapy and 41 percent without induction therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MMF may have a future role in the prevention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of chronic rejection. Among children with chronic rejection, some evidence suggests that substituting MMF for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    may improve renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690816347\">",
"    <span class=\"h4\">",
"     Monitoring and targeting levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been considerable debate regarding the utility of measuring mycophenolic acid levels (MPA). Advocation for MPA monitoring is based on the premise that monitoring will result in avoiding both underdosing, which prevents rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/56-59\">",
"     56-59",
"    </a>",
"    ], and overdosing, which increases the risk of adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/56,58-60\">",
"     56,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter study conducted in France showed significantly fewer treatment failures and acute rejection episodes in the monitoring arm compared to the fixed dose arm with no significant difference in side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/61\">",
"       61",
"      </a>",
"      ]. Within this study, the MPA exposure and MMF dosing were higher in the monitoring arm based on three levels measured over the first three hours post-dose.",
"     </li>",
"     <li>",
"      The Opticept trial in 720 kidney recipients reported the concentration-controlled (CC) monitoring group compared with the fixed dose (FD) group had higher dosing of MMF, and lower rates of treatment failure defined as biopsy-proven acute rejection, allograft loss, and death (23 versus 26 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, results from the FDCC (Fixed Dose versus Concentration Controlled) study performed at 69 international centers showed no benefit in the CC monitoring group compared with the FD group. MPA exposures for both groups were similar at most time points, partly because physicians seemed reluctant to implement substantial dose changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our institution, we monitor MPA levels and target levels between 2 and 4",
"    <span class=\"nowrap\">",
"     &micro;g/mL.",
"    </span>",
"    In addition, we use monitoring levels as a measure of adherence to the immunosuppression plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218194\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of MMF are dose-related. They include diarrhea, vomiting, leukopenia, anemia, and infectious complications. Compared with adults, there is a higher incidence of adverse effects with MMF observed in young children below the age of six years that result in drug discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/64\">",
"     64",
"    </a>",
"    ]. This was illustrated in a study of 24 children who were switched from",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    to MMF because of presumed chronic rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/65\">",
"     65",
"    </a>",
"    ]. MMF had to be stopped in 13 children (54 percent) because of intolerable side effects; by comparison, MMF is discontinued in only about 15 percent of adult renal transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Mycophenolate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, another study of de novo patients treated with MMF in combination with calcineurin inhibitors and corticosteroids reported lower rates of adverse effects in pediatric patients compared with adult patients (4.8 versus 12.5 percent ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/66\">",
"     66",
"    </a>",
"    ]. However, young children (less than six years of age) were more likely to have adverse events compared with older children (6 to 18 years of age) and adults including leukocytopenia (20 versus 6 versus 16 percent), diarrhea (40 versus 29 versus 25 percent), and weight loss (10 versus 2 versus 2 percent), respectively.",
"   </p>",
"   <p>",
"    To address the high rate of adverse events, especially gastroenteric problems, enteric coated mycophenolic acid (EC-MPS) was developed to decrease gastric side effects. In a small cross over study of 10 stable pediatric renal transplant patients, there was a significant improvement in gastrointestinal symptoms when patients were converted from MMF to EC-MPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/67\">",
"     67",
"    </a>",
"    ]. In another small case series, eight pediatric patients switched to EC-MPS reported no subsequent gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/68\">",
"     68",
"    </a>",
"    ]. However, one limitation of EC-MPA is that it cannot be crushed or made into a suspension, forcing practitioners to only use this in patients who can swallow pills whole. In addition, data on target MPA predose levels or algorithms for the calculation of MPA-AUC",
"    <sub>",
"     0-12",
"    </sub>",
"    values generated from MMF-treated patients cannot be applied to patients treated with EC-MPS because the slow release galenics of this preparation lead to a more variable pharmacokinetic profile. EC-MPS has not been approved for pediatric renal transplant recipients in the United States and Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218201\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitors have been mainstays of immunosuppression for pediatric transplantation for the past decade and likely account for the continuing improvement in graft survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Although the choice between the two calcineurin inhibitors is based on center preference,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is the preferred agent because of the increase in adverse cosmetic effects associated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and the decrease rate of acute rejection seen with tacrolimus. In 2007, the NAPRTCS database reported tacrolimus was used in 65 percent of renal transplant recipients, whereas only 11 percent received cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218208\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a metabolite of the fungus, Tolypocladium inflatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/72\">",
"     72",
"    </a>",
"    ]. It acts at an early stage of T lymphocyte activation and inhibits the transcription of IL-2, other cytokines, proto-oncogenes, and cytokine receptors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    doses are higher than those prescribed in adults because the drug appears to have a more rapid metabolism in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/73\">",
"     73",
"    </a>",
"    ]. The recommended starting oral dose of cyclosporin is age dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children aged less than six years: the starting dose is 500",
"      <span class=\"nowrap\">",
"       mg/",
"      </span>",
"      m2 per day divided every eight hours.",
"     </li>",
"     <li>",
"      In children older than six years for patients on combination therapy with steroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      purine synthesis inhibitors: the starting dose is between 12 and 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every 12 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    levels are monitored to ensure that neither under- or overdosing occurs. Dosing is changed to maintain target levels between 150 and 300",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    for the first three to six months post-transplant.",
"   </p>",
"   <p>",
"    Three to six months post-transplant, doses are reduced to 4 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Dose frequency is dependent upon the metabolism rate, which is higher in younger children, and is determined by monitoring trough levels. Long-term trough levels are targeted at 75 to 125",
"    <span class=\"nowrap\">",
"     &micro;g/L.",
"    </span>",
"    In the NAPRTCS registry, the maintenance dosage of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    decreased over time with average CSA doses at one year varying from 4.36 to 8.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/61\">",
"     61",
"    </a>",
"    ]. Although, higher maintenance doses are associated with lower chronic graft rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/73\">",
"     73",
"    </a>",
"    ], it also increases the risk of CSA-associated nephropathy. Data from the NAPRTCS registry shows that less than 15 percent of renal transplant recipients are currently receiving cyclosporine as initial immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is available as a capsule or oral solution. The absorption rates vary among the different preparations and dose adjustments are made based upon trough cyclosporine levels.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has been used in combination with all other immunosuppressants except",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . However, because of the potential of increased risk of post-transplant lymphoproliferative disease (PTLD), the use of the combination of a standard-dose calcineurin inhibitor,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    and corticosteroids should probably be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H690821387\">",
"     'Sirolimus versus calcineurin inhibitor'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690816580\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    include nephrotoxicity, hyperkalemia, hypomagnesemia, hypertension, diabetes mellitus, neurotoxicity, hypertrichosis, gum hyperplasia, dyslipidemia, and increased susceptibility to serious infections. In particular, the adverse cosmetic effects may contribute to nonadherence to medications, especially in adolescent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218215\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) is a cyclic peptide of 11 amino acids derived from the fungus Streptomyces tsukubaensis, which acts via a similar mechanism as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/76\">",
"     76",
"    </a>",
"    ]. It binds to calcineurin, a cytosolic receptor, resulting in inhibition of the translocation of the transcription factor NF-AT (nuclear factor of activated T-cells), which inhibits the transcription of several cytokines. The in-vitro immunosuppressive effect of tacrolimus on lymphocyte activation is 50 to 100 times higher than that of cyclosporine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial oral or nasogastric dose for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is 0.2 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day administered in two divided doses. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/77\">",
"     77",
"    </a>",
"    ]. In some cases, tacrolimus is initially administered intravenously at a dose of 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 24 hours and switched to oral medication within two to three days post-transplant. Target trough whole blood levels are 10 to 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    during the first month, and 5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter. At our center, if patients are rejection free at one year post-transplant, our target trough whole blood levels are further reduced to a range between 3 and 5",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    In 2007, data from the NAPRTCS showed that more than 65 percent of children were being maintained on",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    at 30 days post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ]. Tacrolimus has been used in combination with all other immunosuppressants except",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . However, as noted above with cyclosporine, the combination of a calcineurin inhibitor,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and corticosteroids should be used with caution in children at high risk for developing PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/74\">",
"     74",
"    </a>",
"    ]. There have been several centers reporting the use of tacrolimus as a rescue agent in the setting of both acute and chronic rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690820389\">",
"    <span class=\"h3\">",
"     Comparison between cyclosporine and tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials in adults have shown similar allograft survival outcomes with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    based regimens; however, the incidence of acute rejection and requirement for intensive immunosuppression appears to be less with tacrolimus. Although the toxicity profile between the two agents are similar, studies in adult suggest that tacrolimus provides a significant benefit in improved serum lipid values. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link&amp;anchor=H448642588#H448642588\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Tacrolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, there are limited data comparing graft survival rates between",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 986 children (220 treated with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and 766 with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ), allograft survival was similar between the tacrolimus and cyclosporine groups at one year (97 versus 98 percent) and two years (91 versus 95 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an open-label trial of 192 pediatric patients, there was a lower incidence of acute rejection in patients who were randomly assigned to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      compared to those who received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (37 versus 59 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/83\">",
"       83",
"      </a>",
"      ]. At four year follow-up, patient survival was similar (94 versus 92 percent), however, tacrolimus was associated with better allograft survival (86 versus 69 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from the adult trials and the adverse cosmetic effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are the main reasons for the shift from the use of cyclosporine to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in pediatric renal transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690821271\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity profile of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is similar to that of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    except for the cyclosporine-associated adverse cosmetic effects (hypertrichosis and gum hyperplasia) and dyslipidemia. Side effects of tacrolimus include nephrotoxicity, hypertension, diabetes mellitus, neurotoxicity, and increased susceptibility to serious infection.",
"   </p>",
"   <p>",
"    Although the incidence PTLD appeared to be higher with the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    during the first years of its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], subsequent analysis showed tacrolimus was not associated with a greater risk for development of PTLD compared to other immunosuppressant agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218222\">",
"    <span class=\"h2\">",
"     Mammalian target of rapamycin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (rapamycin), the first mammalian target of rapamycin (mTOR) inhibitor, is a macrolide antibiotic produced by the fungus, Streptomyces hygroscopicus. It blocks the proliferative response of lymphocytes in response to IL-2. Sirolimus is effective in association with calcineurin inhibitors as immunosuppressive agent, but it may increase the nephrotoxic effect of calcineurin inhibitors. As a result, lower doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are recommended when used in combination with sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/88\">",
"     88",
"    </a>",
"    ]. In 2007, data from the NAPRTCS registry demonstrated that sirolimus was used in only 3 percent of pediatric renal transplants recipients 30 day post-transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ]. Another mTOR inhibitor,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/41/20121?source=see_link\">",
"     everolimus",
"    </a>",
"    , has also been used in pediatric renal transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94204396\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is available as an oral preparation, either as a solid or liquid formulation. It was shown to have a prolonged half-life in adults that allowed a single daily dose in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. However, pharmacokinetic studies in children have demonstrated a much shorter half life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Thus, children may require twice-per-day schedules in order to maintain therapeutic levels.",
"   </p>",
"   <p>",
"    Daily dosing is dependent upon the weight of the patient and whether they are on calcineurin therapy. It is critical to determine target trough levels of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    especially with the concomitant use of calcineurin inhibitors, and adjust the dosing accordingly. Current suggestions for therapeutic levels remain speculative and are dependent upon the concomitant use of calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/92,94\">",
"     92,94",
"    </a>",
"    ]. Because of delayed wound healing associated with the use of sirolimus, subsequent protocols avoid early post-transplant use of mTOR inhibitors. Below are therapeutic targets used in various pediatric renal transplant protocols:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early post-transplant period without calcineurin inhibitors, the target range is up to 25",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]. Target levels are reduced to 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      later in the course of transportation.",
"     </li>",
"     <li>",
"      Early post-transplant period with calcineurin inhibitors, the target range is between 10 and 20 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/37,41\">",
"       37,41",
"      </a>",
"      ]. Target levels are reduced to 5 to 10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      later in the course of transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a cohort of 66 pediatric renal transplant patients who received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    , a calcineurin inhibitor and corticosteroids, acute rejection occurred in 10.6 percent of patients and allograft survival was 98 percent at six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/95\">",
"     95",
"    </a>",
"    ]. In a pediatric study, adding",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    to a combination of a calcineurin inhibitor, sirolimus, and steroids did decrease the rejection rate over historical controls; however, there was also an increase in the rate of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/37,41\">",
"     37,41",
"    </a>",
"    ]. It is thought that this combination resulted in over-immunosuppression in high-risk EBV naive pediatric patients and should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94204478\">",
"    <span class=\"h4\">",
"     Sirolimus versus calcineurin inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In renal transplantation, calcineurin inhibitor nephrotoxicity is one risk factor for reduced long-term allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/96\">",
"     96",
"    </a>",
"    ]. In adults,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    is used by some transplant centers in triple-therapy regimens in place of the calcineurin inhibitor.",
"   </p>",
"   <p>",
"    Because of the potential lifetime consequences of immunosuppression in pediatric patients,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    instead of a calcineurin inhibitor in patients with low to moderate immunologic risk would be potentially beneficial. Variable success has been reported with the use of sirolimus in the place of calcineurin inhibitors in pediatric patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study avoiding the use of calcineurin inhibitors, 34 patients received an anti-CD25 monoclonal antibody,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/97\">",
"       97",
"      </a>",
"      ]. The incidence of early acute rejection was high (22 and 32 percent at 6 and 12 months) at three-year follow-up. In addition, four patients withdrew from the study because of significant adverse events, and two developed PTLD.",
"     </li>",
"     <li>",
"      In a retrospective analysis of 19 pediatric patients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity, calcineurin inhibitor withdrawal was attempted with a change to an immunosuppression regimen of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and corticosteroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/98\">",
"       98",
"      </a>",
"      ]. Calcineurin inhibitors were successfully weaned in ten patients, of which seven had improved renal function. In the other nine patients, the dose of calcineurin was decreased with an improvement in renal function in six patients.",
"     </li>",
"     <li>",
"      In a study of 30 pediatric renal transplant patients who were converted from",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      at three months post-transplant, the incidence of acute rejection after conversion was low at 10 percent, but as a group, the average renal function did not improve during follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    as rescue therapy for chronic allograft injury needs to be applied with caution in pediatric patients, especially patients who have advanced allograft dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. There seems to be a point where allograft injury is severe enough that withdrawing calcineurin inhibitors results in no significant clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of the use of this agent in renal transplantation among adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94204403\">",
"    <span class=\"h3\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/41/20121?source=see_link\">",
"     Everolimus",
"    </a>",
"    , the other mTOR inhibitor, has also been used in pediatric renal transplantation. A prospective multicenter open-label study was performed in de novo pediatric renal transplant recipients who received maintenance immunosuppression of everolimus, CSA and corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/101\">",
"     101",
"    </a>",
"    ]. Of the 19 patients who entered the study, 3 discontinued study medication before one year, and 15 of the remaining 16 patients entered the extension study. The graft survival at one year was 100 percent, and there was one graft loss in the group who were in the extension study. Overall, the acute rejection rates and incidence of hyperlipidemia were in line with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    based therapy.",
"   </p>",
"   <p>",
"    In another prospective study of 20 children who initially were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/58/28582?source=see_link\">",
"     basiliximab",
"    </a>",
"    , CSA, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/41/20121?source=see_link\">",
"     everolimus",
"    </a>",
"    therapy was started two weeks after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/102\">",
"     102",
"    </a>",
"    ]. In these patients, the dose of CSA was reduced by 50 percent six months after transplantation, and prednisolone therapy was tapered and discontinued in all patients within nine months after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/103\">",
"     103",
"    </a>",
"    ]. At three year follow-up, there has been no graft or patient loss, and 17 of the 20 patients remain on the original immunosuppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690821387\">",
"    <span class=\"h3\">",
"     Sirolimus versus calcineurin inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In renal transplantation, calcineurin inhibitor nephrotoxicity is one risk factor for reduced long-term allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/96\">",
"     96",
"    </a>",
"    ]. In adults,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    is used by some transplant centers in triple-therapy regimens in place of the calcineurin inhibitor.",
"   </p>",
"   <p>",
"    Because of the potential lifetime consequences of immunosuppression in pediatric patients,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    instead of a calcineurin inhibitor in patients with low to moderate immunologic risk would be potentially beneficial. Variable success has been reported with the use of sirolimus in the place of calcineurin inhibitors in pediatric patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pilot study avoiding the use of calcineurin inhibitors, 34 patients received an anti-CD25 monoclonal antibody,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/97\">",
"       97",
"      </a>",
"      ]. The incidence of early acute rejection was high (22 and 32 percent at 6 and 12 months) at three-year follow-up. In addition, four patients withdrew from the study because of significant adverse events, and two developed PTLD.",
"     </li>",
"     <li>",
"      In a retrospective analysis of 19 pediatric patients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity, calcineurin inhibitor withdrawal was attempted with a change to an immunosuppression regimen of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and corticosteroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/98\">",
"       98",
"      </a>",
"      ]. Calcineurin inhibitors were successfully weaned in ten patients, of which seven had improved renal function. In the other nine patients, the dose of calcineurin was decreased with an improvement in renal function in six patients.",
"     </li>",
"     <li>",
"      In a study of 30 pediatric renal transplant patients who were converted from",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      at three months post-transplant, the incidence of acute rejection after conversion was low at 10 percent, but as a group, the average renal function did not improve during follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    as rescue therapy for chronic allograft injury needs to be applied with caution in pediatric patients, especially patients who have advanced allograft dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. There seems to be a point where allograft injury is severe enough that withdrawing calcineurin inhibitors results in no significant clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of the use of this agent in renal transplantation among adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218229\">",
"    <span class=\"h2\">",
"     Immunosuppression combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance immunosuppression regimens generally consist of a combination of agents with different mechanisms of action. Combination therapy provides a synergistic immunosuppressive effect that reduces the incidence of acute rejection while minimizing the side effects of each individual agent.",
"   </p>",
"   <p>",
"    Most pediatric renal transplant recipients have been treated with triple immunosuppression therapy that consists of corticosteroid (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ), an antimetabolite (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    ), and a calcineurin inhibitor (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there remain significant side effects from this regimen, particularly associated with long-term corticosteroid (eg, growth impairment) and calcineurin inhibitor therapy (eg, chronic nephropathy).",
"   </p>",
"   <p>",
"    Although many centers have tried to minimize the use of corticosteroids or avoid them all together, no best protocol for pediatric renal transplant recipients has been established. As previously discussed, current efforts are directed towards eliminating or minimizing corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcineurin inhibitors used in maintenance immunotherapy. These efforts continue the quest of finding the immunosuppressive regimen that optimizes long-term allograft survival by preventing acute rejection episodes while minimizing long-term significant adverse effects, such as post-transplant lymphoproliferative disorders, growth impairment, and nephropathy. (See",
"    <a class=\"local\" href=\"#H533861718\">",
"     'Corticosteroid withdrawal'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H690821387\">",
"     'Sirolimus versus calcineurin inhibitor'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link\">",
"     \"Complications of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784212492\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal immunosuppressive regimen for children who undergo renal transplantation remains unclear, and there are currently a wide range of approaches using a multiple number of immunosuppressive agents at centers throughout the world.",
"   </p>",
"   <p>",
"    At our institution, most of our patients are enrolled in multicenter clinical trials that use a standard immunosuppression protocol that minimizes the use of corticosteroids. Until daclizumab became unavailable, we used extended dose daclizumab,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and MMF as our standard approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/21\">",
"     21",
"    </a>",
"    ]. When daclizumab became unavailable, we changed induction therapy to a biologic agent (rATG-thymoglobulin) with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    as pre-medication, and maintenance immunosuppression therapy with a calcineurin inhibitor (tacrolimus) and an anti-metabolite (MMF) similar to the approach used at several other centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It is important to note that extended follow-up and further study is needed to determine whether there are increases in the incidence of PTLD and accelerated chronic allograft nephropathy using these agents, in order to provide steroid-free maintenance immunosuppression.",
"   </p>",
"   <p>",
"    In our practice, the following immunosuppressive regimen is used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy consists of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      rATG-thymoglobulin is administered at a dose of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intraoperatively. It is continued postoperatively, and redosed when the absolute lymphocyte count is greater than 100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      up to a total of seven doses (including the intraoperative dose) depending on when",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is started (see below). &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      is given at a dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose of 1 gram) intraoperatively preceding the first rATG-thymoglobulin dose. It is only given thereafter as a premedication (1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      for rATG-thymoglobulin administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance immunosuppression includes the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil at a daily dose of 600",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      and adjusted for signs of myelosuppression.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      is started when the serum creatinine concentration has decreased by at least 50 percent of pretransplant baseline and urine output is greater than 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. The starting dose is 0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      per day administered as two divided oral doses. This is a lower dose than used in other centers because its administration overlaps that of rATG-thymoglobulin for two days. The dose is adjusted to obtain a 12-hour trough blood level of 10 to 12",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      The target trough level is lowered progressively over time. For patients who are rejection free at one year post-transplant, the trough level is maintained at 3 to 5",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The amount of immunosuppression is decreased based on signs or symptoms of excessive immunosuppression, such as leucopenia or problematic viral or other infections. Immunosuppression is increased if the patient develops acute rejection or subclinical rejection based on surveillance biopsies. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218236\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACUTE REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no controlled trials of treatment of acute organ transplant rejection in children. In general, the initial treatment of a rejection episode is with pulse intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , typically given over three consecutive days with a dose between 10 and 30",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    This regimen may be followed by a slow taper of oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , but some centers do not routinely use the oral taper. After bolus therapy, the maintenance dose of corticosteroids is often increased to 1 or 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day, depending upon the severity of the rejection crisis and the response to treatment. This is followed by a slow tapering to prerejection doses.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    consisting of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day has been reported in children with similar rates of rejection reversal to intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the initiation of anti-rejection therapy, the plasma creatinine concentration may continue to increase for three to four days. However, if therapy reverses rejection, creatinine levels should decrease after one week. The rejection episode may be completely reversible with the creatinine level returning to levels similar to those observed prior to the rejection episode. In approximately 40 percent of cases, the serum creatinine remains elevated above baseline which can either be due to chronic damage or ongoing rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/31/38394/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rejection episode may be considered steroid resistant if no improvement is observed in the plasma creatinine 7 to 10 days after initiation of steroid pulse therapy. Steroid resistant, severe, or recurrent episodes are often treated with lymphocyte-depleting antibodies. In some cases, patients who have rejection episodes and have been adherent to their maintenance immunosuppression, alternative immunosuppressive strategies should be considered in addition to treatment of the acute rejection. For example, patients on",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    , a switch to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) may be of benefit. Alternatively, some centers alter the immunosuppression regimen to include a calcineurin inhibitor and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    rather than azathioprine or MMF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Re-evaluation of maintenance immunosuppression is indicated following a rejection episode. One may consider switching immunosuppressive agents. For example, adjustments may include changing to an alternative calcineurin inhibitor or from an antimetabolite (ie, MMF or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/14/10472?source=see_link\">",
"     sirolimus",
"    </a>",
"    to take advantage of the synergism between sirolimus and the calcineurin inhibitors. In addition, assessment of the patient&rsquo;s adherence to the medication regimen is always important.",
"   </p>",
"   <p>",
"    Antibody mediated rejection is treated in a variety of including plasma exchange, high dose intravenous immune globulin, and anti-CD 20 therapy, and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link&amp;anchor=H23#H23\">",
"     \"Acute renal allograft rejection: Treatment\", section on 'Antibody mediated rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35218244\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of immunosuppression in pediatric renal recipients is to find the best immunosuppressive regimen that optimizes allograft survival by preventing acute rejection while minimizing toxicities such as infection, nephrotoxicity, malignancy, and adverse cosmetic effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although data from adult renal transplantation trials are used to help guide management decisions in pediatric patients, immunosuppression often must be modified because of the unique clinical effects of some of these agents in children including their impact on growth.",
"     </li>",
"     <li>",
"      The immunosuppressive regimens used in pediatric patients vary among transplant centers and continue to evolve with the development of new medications. In addition, there are patient-specific factors that should be considered when choosing immunosuppressive agents. (See",
"      <a class=\"local\" href=\"#H2175234\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressive therapy is divided into three categories. (See",
"      <a class=\"local\" href=\"#H2175234\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Induction therapy &ndash; Induction therapy is intensive immunosuppression that is administered during the perioperative period when the risk of acute rejection is highest. It generally includes the use of antibodies directed against T-cell antigens in combination with conventional immunosuppressive therapy (ie, corticosteroids, antimetabolites,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcineurin inhibitors).",
"     </li>",
"     <li>",
"      Maintenance therapy &ndash; Immunosuppressive therapy to prevent acute rejection after the perioperative period.",
"     </li>",
"     <li>",
"      Treatment of acute rejection &ndash; Immunosuppressive therapy to treat acute rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To date, no controlled trials in pediatric renal transplant recipients have verified the benefit of using induction antibody therapy. However, based upon the results from trials in adult renal transplantation recipients and registry data from the North American Pediatric Renal Trials and Collaborative Studies, we recommend that antibody induction therapy should be used in conjunction with conventional immunosuppression in pediatric renal transplant recipients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The use of biological agents (ie, antilymphocyte antibodies and anti-interleukin 2 receptor antibodies) as induction therapy is controversial, and the current choice of induction therapy is center dependent. Considerations in choosing the appropriate biologic agent include the efficacy in the patient population (eg, high-risk or low-risk for graft loss recipients), whether they are on corticosteroid or calcineurin inhibitor minimization protocols, and the side effect profile of the selected immunosuppressive agent(s). (See",
"      <a class=\"local\" href=\"#H35218101\">",
"       'Induction immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the administration of maintenance immunosuppressive therapy to all pediatric renal transplant recipients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Maintenance immunosuppression regimens generally consist of a combination of agents with different mechanisms of action. The most common classes of immunosuppressive agents include corticosteroids (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      ), antimetabolites (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil), and calcineurin inhibitors (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ). However, these drugs are associated with significant side effects, particularly prednisone and the calcineurin inhibitors. As a result, ongoing trials are directed towards identifying regimens that successfully withdraw or minimize the use of these drugs to reduce the adverse effects of these medications without increasing the risk of acute rejection. (See",
"      <a class=\"local\" href=\"#H35218143\">",
"       'Maintenance immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the administration of intravenous pulse",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      to patients with acute allograft rejection (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is at present no consensus for an established immunosuppressive regimen following renal transplantation in children. The immunosuppressive regimen used at Seattle Children&rsquo;s Hospital for patients not on multicenter clinical trials is as follows. (See",
"      <a class=\"local\" href=\"#H784212492\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Induction therapy includes rATG-thymoglobulin (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given intraoperatively and up to five daily doses postoperatively).",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      is given before each rATG-thymoglobulin dose, 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 1 gram) before the first dose, and 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      prior to each subsequent dose.",
"     </li>",
"     <li>",
"      Maintenance therapy includes",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (daily dose of 600",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/1\">",
"      Benfield MR, McDonald RA, Bartosh S, et al. Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2003; 7:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/2\">",
"      Benfield MR, Tejani A, Harmon WE, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005; 9:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/3\">",
"      Feld LG, Stablein D, Fivush B, et al. Renal transplantation in children from 1987-1996: the 1996 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997; 1:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/4\">",
"      Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006; 6:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/5\">",
"      Offner G, Toenshoff B, H&ouml;cker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008; 86:1241.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS 2008 annual report. https://web.emmes.com/study/ped/index.htm (Accessed on July 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/7\">",
"      Kreis H. Antilymphocyte globulins in kidney transplantation. Kidney Int Suppl 1992; 38:S188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/8\">",
"      Khositseth S, Matas A, Cook ME, et al. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation 2005; 79:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/9\">",
"      Chavers BM, Chang YC, Gillingham KJ, Matas A. Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. Transplantation 2009; 88:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/10\">",
"      Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation 2010; 90:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/11\">",
"      Norman DJ, Leone MR. The role of OKT3 in clinical transplantation. Pediatr Nephrol 1991; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/12\">",
"      Seikaly M, Ho PL, Emmett L, Tejani A. The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 2001; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/13\">",
"      Niaudet P, Jean G, Broyer M, Chatenoud L. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 1993; 7:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/14\">",
"      Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/15\">",
"      Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation 2008; 85:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/16\">",
"      Tan HP, Kaczorowski D, Basu A, et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005; 37:4235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/17\">",
"      Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/18\">",
"      Ona ET, Danguilan RA, Africa J, et al. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation. Transplant Proc 2008; 40:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/19\">",
"      Webb NJ, Prokurat S, Vondrak K, et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. Pediatr Nephrol 2009; 24:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/20\">",
"      Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 2010; 10:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/21\">",
"      Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/22\">",
"      Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/23\">",
"      Pape L, Strehlau J, Henne T, et al. Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 2002; 17:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/24\">",
"      Clark G, Walsh G, Deshpande P, Koffman G. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 2002; 17:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/25\">",
"      Offner G, Broyer M, Niaudet P, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation 2002; 74:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/26\">",
"      Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation 2002; 74:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/27\">",
"      H&ouml;cker B, Kovarik JM, Daniel V, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008; 86:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/28\">",
"      Sterkers G, Baudouin V, Ansart-Pirenne H, et al. Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients. Transplant Proc 2000; 32:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/29\">",
"      Dobbels F, Ruppar T, De Geest S, et al. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant 2010; 14:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/30\">",
"      Korsch BM, Fine RN, Negrete VF. Noncompliance in children with renal transplants. Pediatrics 1978; 61:872.",
"     </a>",
"    </li>",
"    <li>",
"     Kirsham RL, Panayi GS. Steroids. In: Immunopharmacology in Autoummune diseases and Transplantation, Rugstad HE, Endressen L, Forre O (Eds), Plenum Press, New York 1992. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/32\">",
"      Beato M. Gene regulation by steroid hormones. Cell 1989; 56:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/33\">",
"      Paliogianni F, Raptis A, Ahuja SS, et al. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 1993; 91:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/34\">",
"      Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 1992; 120:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/35\">",
"      Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996; 61:31.",
"     </a>",
"    </li>",
"    <li>",
"     Ingulli E, Tejani A. Steroid withdrawal after renal transplantation. In: Pediatric Renal Traplantation, Wiley-Liss, New York 1994. p.221.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/37\">",
"      Benfield MR, Bartosh S, Ikle D, et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/38\">",
"      Sutherland S, Li L, Concepcion W, et al. Steroid-free immunosuppression in pediatric renal transplantation: rationale for and [corrected] outcomes following conversion to steroid based therapy. Transplantation 2009; 87:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/39\">",
"      Barletta GM, Kirk E, Gardner JJ, et al. Rapid discontinuation of corticosteroids in pediatric renal transplantation. Pediatr Transplant 2009; 13:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/40\">",
"      H&ouml;cker B, Weber LT, Feneberg R, et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009; 87:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/41\">",
"      McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/42\">",
"      H&ouml;cker B, Weber LT, Feneberg R, et al. Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrol Dial Transplant 2010; 25:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/43\">",
"      Lau KK, Berg GM, Schjoneman YG, et al. Extended experience with a steroid minimization immunosuppression protocol in pediatric renal transplant recipients. Pediatr Transplant 2010; 14:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/44\">",
"      Chavers BM, Rheault MN, Gillingham KJ, Matas AJ. Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol. Pediatr Transplant 2012; 16:704.",
"     </a>",
"    </li>",
"    <li>",
"     Bach JF. Mode of action of thiopurines: Azathioprine and 6-mercaptopurine. In: Immunopharmacology in Autoimmune Diseases and Transplantation, Rugstad HE, Endressen L, Forre O (Eds), Plenum Press, New York 1992. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/46\">",
"      Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80:S254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/47\">",
"      Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): Mechanisms of action and effects in transplantation. Transplant Rev 1993; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/48\">",
"      Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/49\">",
"      Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/50\">",
"      A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/51\">",
"      Jungraithmayr TC, Wiesmayr S, Staskewitz A, et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007; 83:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/52\">",
"      Cransberg K, Marlies Cornelissen EA, Davin JC, et al. Improved outcome of pediatric kidney transplantations in the Netherlands -- effect of the introduction of mycophenolate mofetil? Pediatr Transplant 2005; 9:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/53\">",
"      H&ouml;cker B, Weber LT, Bunchman T, et al. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Pediatr Transplant 2005; 9:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/54\">",
"      Ferraris JR, Tambutti ML, Redal MA, et al. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000; 70:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/55\">",
"      Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003; 76:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/56\">",
"      Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006; 6:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/57\">",
"      Tredger JM, Brown NW. Mycophenolate: better value through monitoring? Transplantation 2006; 81:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/58\">",
"      Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/59\">",
"      Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/60\">",
"      Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/61\">",
"      Le Meur Y, B&uuml;chler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/62\">",
"      Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009; 9:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/63\">",
"      Van Gelder T, Silva HT, de Fijter H, et al. A prospective, randomized study comparing fixed dose vs concentration controlled MMF regimens for de nova patients following renal transplantation (the FDCC trial). Am J Transplant 2006; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/64\">",
"      Bunchman T, Navarro M, Broyer M, et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001; 16:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/65\">",
"      Butani L, Palmer J, Baluarte HJ, Polinsky MS. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999; 68:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/66\">",
"      H&ouml;cker B, van Gelder T, Martin-Govantes J, et al. Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant 2011; 26:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/67\">",
"      Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008; 12:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/68\">",
"      Vilalta Casas R, Vila L&oacute;pez A, Nieto Rey JL, et al. Mycophenolic Acid reaches therapeutic levels whereas mycophenolate mofetil does not. Transplant Proc 2006; 38:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/69\">",
"      Tejani A, Stablein DM, Donaldson L, et al. Steady improvement in short-term graft survival of pediatric renal transplants: the NAPRTCS experience. Clin Transpl 1999; :95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/70\">",
"      Colombani PM, Dunn SP, Harmon WE, et al. Pediatric transplantation. Am J Transplant 2003; 3 Suppl 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/71\">",
"      Tejani A, Ho PL, Emmett L, et al. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002; 2:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/72\">",
"      Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/73\">",
"      Harmon WE, Sullivan EK. Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation. Kidney Int Suppl 1993; 43:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/74\">",
"      Harmon WE, McDonald RA, Reyes JD, et al. Pediatric transplantation, 1994-2003. Am J Transplant 2005; 5:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/75\">",
"      Magee JC, Bucuvalas JC, Farmer DG, et al. Pediatric transplantation. Am J Transplant 2004; 4 Suppl 9:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/76\">",
"      Klintmalm GB. FK 506: an update. Clin Transplant 1994; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/77\">",
"      Shaw LM, Holt DW, Keown P, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/78\">",
"      Birk PE, Cook ME, Schmidt WJ, Chavers BM. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. Transplant Proc 1996; 28:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/79\">",
"      Shapiro R. Tacrolimus in pediatric renal transplantation: a review. Pediatr Transplant 1998; 2:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/80\">",
"      Shapiro R, Scantlebury VP, Jordan ML, et al. FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol 1995; 9 Suppl:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/81\">",
"      McKee M, Segev D, Wise B, et al. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg 1997; 32:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/82\">",
"      Neu AM, Ho PL, Fine RN, et al. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003; 7:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/83\">",
"      Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/84\">",
"      Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005; 9:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/85\">",
"      Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol 1995; 9:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/86\">",
"      Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/87\">",
"      Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/88\">",
"      Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003; 75:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/89\">",
"      Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/90\">",
"      Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/91\">",
"      Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/92\">",
"      Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004; 8:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/93\">",
"      Sindhi R, Webber S, Goyal R, et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. Transplant Proc 2002; 34:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/94\">",
"      Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/95\">",
"      Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatr Transplant 2005; 9:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/96\">",
"      Schwartz C, Oberbauer R. Calcineurin inhibitor sparing in renal transplantation. Curr Opin Organ Transplant 2006; 11:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/97\">",
"      Harmon W, Meyers K, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006; 17:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/98\">",
"      H&ouml;cker B, Feneberg R, K&ouml;pf S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006; 10:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/99\">",
"      Hymes LC, Warshaw BL, Amaral SG, Greenbaum LA. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008; 12:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/100\">",
"      Weintraub L, Li L, Kambham N, et al. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant 2008; 12:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/101\">",
"      Ettenger R, Hoyer PF, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant 2008; 12:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/102\">",
"      Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010; 10:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/103\">",
"      Pape L, Lehner F, Blume C, Ahlenstiel T. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011; 92:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/104\">",
"      Orta-Sibu N, Chantler C, Bewick M, Haycock G. Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Br Med J (Clin Res Ed) 1982; 285:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/31/38394/abstract/105\">",
"      McDonald R, Ho PL, Stablein DM, et al. Rejection profile of recent pediatric renal transplant recipients compared with historical controls: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2001; 1:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6128 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38394=[""].join("\n");
var outline_f37_31_38394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35218244\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35218094\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2175234\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35218101\">",
"      INDUCTION IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2175257\">",
"      Antibody induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218108\">",
"      - Antilymphocyte antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35218115\">",
"      Polyclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35218122\">",
"      Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218129\">",
"      - Anti-interleukin 2 receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86243149\">",
"      Nonbiological agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35218143\">",
"      MAINTENANCE IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694166221\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35222050\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218157\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533861718\">",
"      - Corticosteroid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H176355543\">",
"      Recurrent renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35218164\">",
"      Antimetabolic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218173\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35218180\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218187\">",
"      - Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H690816347\">",
"      Monitoring and targeting levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35218194\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35218201\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218208\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H690816580\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35218215\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690820389\">",
"      - Comparison between cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H690821271\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35218222\">",
"      Mammalian target of rapamycin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94204396\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H94204478\">",
"      Sirolimus versus calcineurin inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94204403\">",
"      - Everolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H690821387\">",
"      - Sirolimus versus calcineurin inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35218229\">",
"      Immunosuppression combinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H784212492\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35218236\">",
"      TREATMENT OF ACUTE REJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35218244\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6128|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/60/27599\" title=\"figure 1\">",
"      Trend of induction therapy in pediatric renal tranplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6128|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/44/15042\" title=\"table 1\">",
"      Drug interactions with immunosuppressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23543?source=related_link\">",
"      General principles of kidney transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40680?source=related_link\">",
"      Outcomes of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_31_38395="Contraindications to coronary angiography";
var content_f37_31_38395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative contraindications to coronary angiography",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acute renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal failure secondary to diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained fever, which may be due to infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated active infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe uncontrolled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe symptomatic electrolyte imbalance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe lack of cooperation by patient due to",
"psychological or severe systemic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe concomitant illness that drastically shortens",
"life expectancy or increases risk of therapeutic interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refusal of patient to consider definitive therapy such",
"as PTCA, CABG, or valve replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digitalis intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Documented anaphylactoid",
"reaction to angiographic contrast media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe peripheral vascular disease limiting vascular",
"access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompensated heart failure or acute pulmonary",
"edema&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic valve endocarditis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTCA: percutaneoas transluminal coronary angioplasty; CABG: coronaryartety bypass graft.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Scanlon, PJ, Faxon, DP, Audet, AM, et al, J Am Coll Cardiol 1999; 33:1756.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38395=[""].join("\n");
var outline_f37_31_38395=null;
var title_f37_31_38396="Systemic antibiotics for Acinetobacter infections in adults";
var content_f37_31_38396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systemic antibiotics for treatment of Acinetobacter infection in adults with normal renal function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        2 g intravenously every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime",
"       </td>",
"       <td>",
"        2 g intravenously every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin-sulbactam*",
"       </td>",
"       <td>",
"        3 g intravenously every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem-cilastatin",
"       </td>",
"       <td>",
"        0.5 to 1 g intravenously every 6 hours to 1 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"       <td>",
"        1 g intravenously every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doripenem",
"       </td>",
"       <td>",
"        0.5 g intravenously every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 to 2.5 mg/kg intravenously every 8 to 12 hours or 7 mg/kg every 24 to 48 hours depending on creatinine clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 to 2.5 mg/kg intravenously every 8 to 12 hours or 7 mg/kg every 24 to 48 hours depending on creatinine clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        5 to 7.5 mg/kg intravenously every 8 hours or 15 mg/kg every 24 to 48 hours depending on creatinine clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg intravenously every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colistin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5 to 5 mg/kg/day intravenously in&nbsp;two to four&nbsp;divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tigecycline",
"       </td>",
"       <td>",
"        100 mg single dose, followed by 50 mg intravenously every 12 hours; 100 mg every 12 hours in serious infections",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table lists typical doses for use in Acinetobacter infections among patients with normal renal function.&nbsp;Antimicrobial susceptibility should be confirmed for clinical isolates.",
"    <div class=\"footnotes\">",
"     * Sulbactam is the active component. Dose is expressed as sum of ampicillin and sulbactam.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Dose is expressed as colistin base. 1 mg colistin base = 30,000 international units. In setting of critical illness a loading dose may be administered (depending on clinical circumstances including renal function): 5 to 7.5 mg/kg single dose",
"      <sup>",
"       [1]",
"      </sup>",
"      .",
"      <br>",
"       <sup>",
"        &Delta;",
"       </sup>",
"       Aminoglycosides and fluoroquinolones are generally used in combination with another agent.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38396=[""].join("\n");
var outline_f37_31_38396=null;
var title_f37_31_38397="Clopidogrel outcome stenting";
var content_f37_31_38397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Clopidogrel reduces event rate after coronary stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 328px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the PCI CURE trial of 2658 patients who underwent a percutaneous coronary intervention (PCI), clopidogrel, administered with aspirin for six days before the intervention and continued for four weeks after, significantly reduced the 30-day and one-year incidence of cardiovascular death, myocardial infarction, or repeat revascularization compared to aspirin alone.",
"    <div class=\"footnotes\">",
"     A: median time from randomization to PCI; B: 30 days after median time of PCI.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Mehta HR, Yusuf S, Peters RJ, et al. Lancet 2001; 358:527.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38397=[""].join("\n");
var outline_f37_31_38397=null;
var title_f37_31_38398="Cystic fibrosis antibiotics";
var content_f37_31_38398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous antibiotics for treating exacerbations of cystic fibrosis lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bacteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        S. aureus (methicillin sensitive)",
"       </td>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         100 mg/kg per day in 3 or 4 divided doses",
"        </span>",
"       </td>",
"       <td>",
"        1.5 g every 6 hours, or 2 g every 8 hours",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         100 to 200 mg/kg per day in 4 or 6 divided doses",
"        </span>",
"       </td>",
"       <td>",
"        2 g every 4 to 6 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        S. aureus (methicillin resistant)",
"       </td>",
"       <td>",
"        Vancomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         60 mg/kg per day in 4 divided doses",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         45 to 60 mg/kg per day in 3 divided doses",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Target trough levels are 15-20 mcg/mL.",
"        </span>",
"        Oral or IV linezolid",
"        <sup>",
"         &Delta;",
"        </sup>",
"        can replace vancomycin if the latter cannot be used.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"12\">",
"        P. aeruginosa",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </td>",
"       <td rowspan=\"11\">",
"        Oral or IV ciprofloxacin",
"        <sup>",
"         &loz;",
"        </sup>",
"        may replace the aminoglycoside if the pseudomonas is sensitive to it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Piperacillin-tazobactam",
"        <sup>",
"         &sect;",
"        </sup>",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        350 to 450 mg/kg",
"        <sup>",
"         &yen;",
"        </sup>",
"        per day in 4 divided doses&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.5 g every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ticarcillin-clavulanate",
"        <sup>",
"         &sect;",
"        </sup>",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        300 to 400 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"        per day in 4 or 6 divided doses&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.1 g every 4 to 6 hours&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ceftazidime",
"       </td>",
"       <td class=\"sublist_other\">",
"        <span class=\"sublist_other\" style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         150 mg/kg per day in 3 divided doses",
"        </span>",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Imipenem-cilastatin",
"       </td>",
"       <td class=\"sublist_other\">",
"        60 to 100 mg/kg per day in 4 divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5-1 g every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Meropenem",
"       </td>",
"       <td class=\"sublist_other\">",
"        120 mg/kg per day in 3 divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tobramycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.3 mg/kg&nbsp;every 8 hours,&nbsp;or 10 to 12 mg/kg every 24 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.3 mg/kg every 8 hours,&nbsp;or 10 to 12&nbsp;mg/kg every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amikacin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5 to 10 mg/kg&nbsp;every 8 hours,&nbsp;or 20 to 30 mg/kg every 24 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5 to 10 mg/kg&nbsp;every 8 hours,&nbsp;or 20 to 30 mg/kg every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        &nbsp;&nbsp;&nbsp;",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Colistin (colistimethate sodium)&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5 to 5 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"        (colistin base) per day in 3 divided doses&nbsp;&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5 to 5 mg/kg (colistin base)&nbsp;per day in 3 divided doses; maximum single dose 100 mg&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        IMPORTANT: Dose units and recommended dosing regimens vary by product and country. Doses shown here are specific to US-licensed information for Coly-Mycin M&reg;. Consult LexiComp reference included with UpToDate and local official product information for details before using this agent.&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"12\">",
"        S. aureus (methicillin sensitive), and P. aeruginosa",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        <strong>",
"         One of the following:",
"        </strong>",
"       </td>",
"       <td rowspan=\"11\">",
"        Oral or IV ciprofloxacin",
"        <sup>",
"         &loz;",
"        </sup>",
"        may replace the aminoglycoside if the pseudomonas is sensitive to it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Piperacillin-tazobactam",
"       </td>",
"       <td class=\"sublist_other\">",
"        350 to 450&nbsp;mg/kg",
"        <sup>",
"         &yen;",
"        </sup>",
"        per day in 4 divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.5 g every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ticarcillin-clavulanate",
"       </td>",
"       <td class=\"sublist_other\">",
"        300 to 400&nbsp;mg/kg",
"        <sup>",
"         ",
"        </sup>",
"        per day in 4 or 6 divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.1 g every 4 to 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cefepime",
"       </td>",
"       <td class=\"sublist_other\">",
"        150 mg/kg per day in 3 divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Imipenem-cilastatin",
"       </td>",
"       <td class=\"sublist_other\">",
"        60 to 100 mg/kg per day in 4 divided doses",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5 to 1 g every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Meropenem",
"       </td>",
"       <td class=\"sublist_other\">",
"        40 mg/kg every 8 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tobramycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.3 mg/kg&nbsp;every 8 hours,&nbsp;or 10 to 12&nbsp;mg/kg every 24 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.3 mg/kg&nbsp;every 8 hours,&nbsp;or 10 to 12&nbsp;mg/kg every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amikacin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5 mg/kg&nbsp;every 8 hours,&nbsp;or 20 to 30 mg/kg every 24 hours",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5 mg/kg&nbsp;every 8 hours,&nbsp;or 20 to 30 mg/kg every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"3\">",
"        &nbsp;&nbsp;&nbsp;",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Colistin (colistimethate sodium)&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5 to 5 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"        (colistin base)&nbsp;per day in 3 divided doses&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.5 to 5 mg/kg (colistin base) per day in 3 divided doses; maximum single dose 100 mg&nbsp;",
"       </td>",
"       <td>",
"        IMPORTANT: Dose units and recommended dosing regimens vary by&nbsp;product and country. Doses shown here are specific to US-licensed information for Coly-Mycin M&reg;. Consult LexiComp reference included with UpToDate and local official product information for details before using this agent.&nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        S. aureus (methicillin resistant), and P. aeruginosa",
"       </td>",
"       <td>",
"        Vancomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        ,",
"        <strong>",
"         plus",
"        </strong>",
"        same antibiotics as P. aeruginosa alone listed above",
"        <strong>",
"         (3 antibiotics total)",
"        </strong>",
"       </td>",
"       <td>",
"        60&nbsp;mg/kg per day in 4 divided doses",
"       </td>",
"       <td>",
"        45 to 60 mg/kg per day in 3 divided doses",
"       </td>",
"       <td>",
"        Oral or IV linezolid",
"        <sup>",
"         &Delta;",
"        </sup>",
"        can replace vancomycin if the latter cannot be used.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The table contains recommended choices of antibiotics based on the type of bacteria isolated. The selection should be modified based on results of sensitivity testing and renal function. The doses given here are typical for patients with CF. Higher and/or more frequent dosing of some antibiotics is often required for CF patients as compared to patients without CF, and a wider range of dose requirements is to be expected.",
"    <div class=\"footnotes\">",
"     * The dose given to children should not generally exceed that for adults.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Monitor blood levels to ensure efficacy and avoid toxicity. The dose and frequency from a previous course of treatment may be used initially if serum concentrations were in the target range, and if creatinine clearance is not substantially changed, but drug levels should still be monitored. If the patient is overweight, dose aminoglycoside initially using ideal body weight or dosing weight. A calculator for ideal body weight and dosing weight&nbsp;in adults is available in UpToDate.",
"      <br>",
"       &Delta; Linezolid dose for children up to age 12 years is 10 mg/kg every 8 hours orally or intravenously.&nbsp; For children age over 12 years and adults, 600 mg orally or intravenously every 12 hours.",
"       <br>",
"        &loz; Oral ciprofloxacin dose for children is 40&nbsp;mg/kg per day (up to 1.5 grams daily) in two divided doses or 30 mg/kg per day intravenously (up to 1.2 grams daily) in two or three divided doses.&nbsp;For adults, ciprofloxacin dosing is 750 mg orally twice per day or 400 mg intravenously three times per day.",
"        <br>",
"         &sect; For treatment of P. aeruginosa without methicillin-sensitive S. aureus (MSSA), piperacillin without tazobactam or ticarcillin without clavulanate can be used where available, in addition to an aminoglycoside.",
"         <br>",
"          &yen; Of piperacillin component.",
"          <br>",
"           &Dagger;&nbsp;Of ticarcillin component.",
"           <br>",
"            &dagger; If the patient is overweight, dose colistin initially using ideal body weight. A calculator for ideal body weight in adults is available in UpToDate.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38398=[""].join("\n");
var outline_f37_31_38398=null;
var title_f37_31_38399="TMJ dislocation";
var content_f37_31_38399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TMJ dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The temporomandibular joint (TMJ) is the articulation of the temporal and mandibular bones. TMJ dislocation occurs when the condyle travels anteriorly along the articular eminence and becomes locked in the anterior superior aspect of the eminence, preventing closure of the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_31_38399=[""].join("\n");
var outline_f37_31_38399=null;
